Stockwinners Market Radar for November 29, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:30 EST Cathie Wood's ARK Investment bought 476K shares of Palantir on Monday

20:27 EST Hologic's COVID-19 test detects omicron variant - The company states: "Hologic announced that its three SARS-CoV-2 tests all detect the recently emerged omicron variant of the coronavirus that causes COVID-19. Aptima and Panther Fusion tests run on Hologic's fully automated Panther(R) and Panther Fusion systems, respectively, which provide initial results in approximately three hours and can process more than 1,000 tests in 24 hours."

19:52 EST Accenture announces extended relationship with AWS - The company states: "Accenture (ACN) announced the renewal of its joint business group with Amazon (AMZN) Web Services, or AWS. Building on a 13-year relationship, Accenture and AWS will make an additional joint investment over the next five years to help clients spur innovation on the Cloud Continuum and accelerate business value at scale by delivering solutions through the Accenture AWS Business Group. Over the next five years, Accenture will develop a range of new accelerators to address the biggest challenges in cloud migrations with the goal of enabling AWS innovations to be adopted up to 50% faster. As part of this investment, Accenture will also continue to invest in data-driven solutions for talent development and organizational change, which are critical and often cited as a key barrier to realizing cloud value. The extended relationship will help clients achieve industry differentiation by tapping into the unparalleled AABG joint portfolio of 175 assets and 20,000 cloud specialists who hold 24,000 AWS certifications - making Accenture among the top systems integrators in the world with vast AWS resources. To date, Accenture and AWS have co-created nearly 40 solutions for 16 industries with proven use-case relevance in order to jumpstart client value."

18:04 EST Atlanticus Holdings' director Rosencrants sells 14,720 common shares - In a regulatory filing, Atlanticus Holdings director Thomas Rosencrants disclosed the sale of 14,720 common shares of the company on November 24 at a price of $64.49 per share.

17:22 EST Chatham Asset Management to acquire R.R. Donnelley for $10.25 per share in cash

17:14 EST Lockheed Martin awarded $124.9M Air Force contract modification - Lockheed Martin was awarded a $124.9M firm-fixed-price contract modification to a previously awarded contract for Lot Four and Five of Long Range Anti-Ship Missiles and tooling and test equipment. The contract modification provides for the purchase of an additional 42 Long Range Anti-Ship Missiles and 24 Weapons Data Links in support of Lot Six. Work is expected to be completed by September 22, 2025. This award is the result of a sole-source acquisition. FY22 Navy weapons procurement funds in the amount of $124,9M are being obligated at time of modification award. The total cumulative face value of the contract is $549.67M. Air Force Life Cycle Management Center is the contracting activity.

17:02 EST Turquoise Hill confirms approval of short-term increase in OT mine budget - Turquoise Hill Resources Ltd. announced that, in light of the progress made in the ongoing negotiations between the Government of Mongolia, Rio Tinto and the company, the board of OT LLC approved a bridging budget of $75M to continue to progress critical activities in the Oyu Tolgoi, OT, underground mine development project. The company expects that the approved increase should be sufficient to sustain work on the development of the OT underground mine up to mid January 2022. While the company believes that the decision to approve the bridging budget was a necessary and positive step in the near term, the company cautions that there can be no assurance that the OT board will approve any future necessary additional investments to further progress underground development and accordingly OT LLC remains at risk of having to slow down further work on the underground development.

17:00 EST RGC Resources raises quarterly dividend to 19.5c from 18.5c per share - The dividend will be paid on February 1, 2022 to shareholders of record on January 18, 2022.

16:59 EST Party City director buys 6K shares of common stock - In a regulatory filing, Party City disclosed that its director Steven Collins bought 6K shares of common stock in a total transaction size of $37.1K, boosting his stake by about 4%. Shares of Party City are up 2.1% after-hours at $5.95 per share.

16:38 EST National Health Investors collects 82.7% of contractual cash due for November - National Health Investors provided a business update regarding its monthly contractual cash collections and average occupancy from its three largest senior housing operators. NHI agreed to defer $1.0 million in rent due for November from Bickford Senior Living. NHI agreed to defer approximately $0.5 million in rent for two other tenants in November which is expected to be repaid with interest. As previously disclosed, NHI has agreed with Bickford to defer $4.5 million in contractual rent due for the fourth quarter of 2021 and expects to grant up to $4.0 million in the first quarter of 2022. NHI has collected 82.7% of contractual cash due for November. The remaining balance for the month is comprised of the following: 3.8% in deferrals related to Bickford; 1.8% in deferrals agreed to with two tenants; 8.3% in unpaid rent related to the legacy Holiday properties; 2.8% related to amounts expected to be collected; and 0.6% related to lower forecasted revenue from transitioned properties prior to the start of the pandemic. For the fourth quarter to date, NHI has collected 81.1% of contractual cash due. The remaining balance for the quarter is comprised of the following: 6.7% in deferrals related to Bickford; 1.8% in deferrals agreed to with two tenants; 8.3% in unpaid rent related to the legacy Holiday properties; 1.5% related to amounts expected to be collected; and 0.6% related to lower forecasted revenue from transitioned properties prior to the start of the pandemic.

16:34 EST Kubient names Mitchell Berg as CTO - Kubient announced ad-tech industry veteran, Mitchell Berg has joined as the company's CTO. In this role, Berg will report directly to Paul Roberts, founder, chairman, CSO, and CEO. Berg adds more than 20 years of technology, engineering, and executive management experience to the Kubient team. Most recently, Berg served as CTO for Koddi. Under his leadership, Berg will further develop the company vision for its technology offerings, including Kubient's product, Kubient Artificial Intelligence, or KAI, as well as work closely with the company's data science team.

16:32 EST Air Lease delivers first of six new Airbus A321-200neo jets to China - Air Lease (AL) announced the delivery of one new Airbus (EADSY) A321-200neo aircraft on long-term lease to China Airlines. Featuring Pratt & Whitney PW1133G-JM engines, this is the first of six new A321-200neos confirmed to deliver to the airline from ALC's orderbook with Airbus. This aircraft is the first A321neo to deliver to China Airlines. "ALC is honored to be the first to introduce the A321neo to our long-time customer China Airlines. The A321neo will become the backbone of China Airlines' single-aisle fleet, providing fleet expansion and modernization, and elevation of their passenger experience to new levels. The greater fuel efficiency and operating flexibility of the A321neo will also maximize profitability and further China Airlines environmental sustainability goals," said John L. Plueger, Chief Executive Officer and President of Air Lease Corporation.

16:31 EST Olema issues statement on falsified information circulating on social media - Olema Pharmaceuticals has been alerted to falsified information circulating on social media relating to the company's planned poster presentation for the Phase 1 dose-escalation portion of the ongoing Phase 1/2 clinical trial of OP-1250 at the San Antonio Breast Cancer Symposium, or SABCS. The falsified poster image was not released or authorized by the company.

16:23 EST CareDx CFO buys $211.7K in common stock - In a regulatory filing, CareDx disclosed that its CFO Ankur Dhingra bought 5K shares of common stock on November 24th in a total transaction size of $211.7K, boosting his stake by 34%.

16:18 EST Werner acquires NEHDS Logistics for $64M - Werner Enterprises "announced it has signed a definitive agreement and has closed on the acquisition of NEHDS, based in Monroe, Connecticut, for a purchase price of $64M, which includes a $4M earnout. NEHDS operates a fleet of over 400 delivery trucks primarily in the Northeast and Midwest U.S. corridors. NEHDS delivers primarily big and bulky products using 2-person delivery teams performing residential and commercial deliveries through a network of 19 cross dock, warehouse and customer facilities. Werner financed the transaction through a combination of cash on hand and existing credit facilities. Beginning in fourth quarter 2021, NEHDS financial results will be included in the Werner Logistics segment."

16:16 EST Graham CFO Jeffrey Glajch to retire - Graham announced that Jeffrey F. Glajch, CFO, who has served as CFO for 13 years, plans to retire in the second calendar quarter of 2022 following the appointment of his successor. The company has initiated a comprehensive external search to identify a successor for this role.

16:14 EST Erytech gets US patent directed to sequential use of methioninase against tumor - Erytech Pharma announced the granting of US patent 11,141,468, covering methods of treating solid tumors by administering methioninase and asparaginase. In total, ERYTECH's IP portfolio now includes 16 global patent families with over 310 patents and 45 applications. These patent families protect ERYTECH's proprietary red blood cell encapsulation technologyts therapeutics for Oncology, Rare Metabolic Diseases, and Immune Modulation, as well as its methods for producing Cargo-Loaded Red Cell Extracellular Vesicles. US 11,141,468, entitled "Method of treating a mammal, including human, against cancer using methionine and asparagine depletion", emphasizes ERYTECH's continuing innovation in the delivery of safe and effective enzymatic activity for depriving tumors of essential nutrients. Corresponding family members have also recently been allowed in Europe, China, and Korea. As disclosed in the patent, ERYTECH scientists determined that certain solid tumors including gastric cancer were unexpectedly sensitized to treatment with asparaginase subsequent to prior treatment with methioninase. And while this finding highlights the complexity of the overarching "tumor starvation" approach, it also demonstrates the potential of the approach to weaken cancer cells, ideally rendering them more susceptible to lower levels of standard of care chemotherapies. Of note, the claims cover the method of treatment irrespective of whether the two enzymes are encapsulated in red blood cells.

16:10 EST Adagene receives FDA clearance of ADG116 IND application - Adagene announced that the FDA has cleared the investigational new drug, or IND, application to proceed with a Phase 1b/2 clinical trial of its anti-CTLA-4 monoclonal antibody, or mAb, ADG116, in combination with the anti-PD-1 antibody, pembrolizumab. The global trial will evaluate patients with advanced/metastatic solid tumors at multiple sites in the U.S. and Asia Pacific. The ADG116-P001 trial is expected to dose the first patient in early 2022, and is designed to evaluate the safety and tolerability, determine the maximum tolerated dose, and assess preliminary efficacy of the combination of ADG116 and pembrolizumab. Additionally, the ongoing ADG116-1003 trial is on track to expand with two combination cohorts investigating safety and preliminary efficacy of ADG116 with either toripalimab or ADG106 in patients with advanced/metastatic solid tumors.

16:07 EST Rapid7 appoints Tim Adams as CFO - Rapid7 announced the appointment of Tim Adams as CFO effective January 3, 2022. Adams will assume the CFO role from current Rapid7 CFO, Jeff Kalowski, who announced his retirement earlier this year after serving approximately five years with Rapid7. Upon joining the company Adams will report directly to Rapid7's chairman and CEO, Corey Thomas. Kalowski will remain in an advisory capacity through the transition period in order to ensure a smooth and orderly transition of responsibilities. Adams joins Rapid7 from BitSight Technologies, where he has served as CFO since April 2020.

16:06 EST Snow Lake Resources receives government grant for $62,000 CAD - Snow Lake Resources provided an update on it's continuing progress in executing a strategic path to production. The company has received a grant from the Manitoba Chambers of Commerce, Manitoba Mineral Development Fund in the amount of $62,000 CAD to be utilized in support of our UAV drone magnetic survey that has been scheduled for mid-December and to be completed by EarthEx Geophysical Solutions Inc. of Selkirk, Manitoba. Pegmatite exploration can be supported by magnetic mapping in numerous ways, including mapping of the structural fabric controlling the crystallization, as well as detection of contrasts in magnetic susceptibility with neighboring lithologies. A historic fixed wing SPECTREM survey in the area shows a correlation between the Thompson Brothers Lithium Deposit and a magnetic low trend. However, the data set lacks sufficient resolution for accurate and efficient drill targeting. The EarthEx drone mag system is known to provide the highest resolution aeromagnetic maps currently in production. Furthermore, EarthEx has previously established through property testing in 2019 that the magnetic susceptibility of the TBL pegmatite is subdued relative to the host rock lithologies , providing a potential method for tracking the deposits magnetic signature and identifying other surrounding targets by using high-resolution magnetometry. The survey utilizes the latest advancements in geophysical drone technology, allowing it to fly lower than other systems. We believe the survey will give Snow Lake credible and critical data to help further identify anomalies that can potentially host lithium pegmatite targets for additional resource expansion. To date Snow Lake has only explored about 5% of its property and this new generation of geophysical drone survey will provide an abundance of data to support future prospecting and drilling programs. Chuck Davidson, President and CEO of the Manitoba Chambers of Commerce and Board Chair for the Manitoba Mineral Development Fund additionally commented "Manitoba has a proud mining legacy for over a century and Snow Lake Lithium will ensure its continuity for the next century as Manitoba establishes itself as a critical member of the EV supply chain while playing an integral role in combatting climate change. We look forward to working with Snow Lake Lithium as they progress to production and beyond." Philip Gross CEO of Snow Lake Lithium commented "We are grateful for the support from the Manitoba government which is a vote of confidence in Snow Lake but more importantly demonstrates the constructive nature of our collaboration and relationship as we strategically execute on our path to lithium production. We look forward to working closely with the government of Manitoba in the coming months and years as we help to establish the province as a key facilitator in the North American fleet electrification."

16:06 EST National Vision raises share repurchase authorization to $100M from $50M - National Vision Holdings announced that its Board of Directors has authorized an increase by $50 million to $100 million in the company's share repurchase program. Since the original $50 million program was authorized on November 8, 2021, approximately 1.0 million shares have been repurchased for a total consideration of $48.4 million. Reade Fahs, chief executive officer, stated, "The share repurchase authorization was initially established with the principal intent of offsetting share dilution related to equity grants. Although that objective remains, we also believe that the current share price offers the Company the ability to purchase shares at an attractive price which will benefit our long-term stockholders. We remain confident in our business model, and our ability to continue to generate strong cash flows and deliver sustainable growth." The Board's authorization permits the Company to make purchases of its Common Stock from time to time in the open market or privately negotiated transactions, and pursuant to pre-set trading plans meeting the requirements of all applicable securities laws and regulations. Shares may be repurchased under the program through December 30, 2023. The timing and amounts of any such repurchases will depend on a variety of factors, including the market price of the Company's shares and general market and economic conditions. The Company expects to fund the share repurchases using cash on hand.

16:02 EST Central Valley Community names Blaine Lauhon as new Chief Banking Officer - James J. Kim, President and CEO of Central Valley Community Bancorp is proud to announce the promotion of Blaine Lauhon to Executive Vice President, Chief Banking Officer, effective November 29, 2021. Lauhon will lead the strategic direction, management and profitability of CVCB's Banking Services division.

16:00 EST AERC Stock trading resumes

15:35 EST BARDA to negotiate contract with Chimerix for smallpox therapeutic - A notice of intent dated Nov 29 was posted to the SAM.gov website, which states that the Office of the Biomedical Advanced Research and Development Authority, or BARDA, intends to negotiate a hybrid Cost Plus Fixed Fee and Firm Fixed Price sole source contract with Chimerix for the development and procurement of a smallpox therapeutic with a mechanism of action distinct from that of TPOXX and with an NDA accepted by the FDA. "The Government intends to negotiate solely with Chimerix, Inc. per FAR 6.302-1 as no other source will satisfy agency requirements," the notice states. Reference Link

15:23 EST Olema Pharmaceuticals trading halted, news pending

15:04 EST Justice Department announces settlement with Gap over discrimination claims - The Department of Justice has announced a settlement with Gap, resolving claims that Gap violated the Immigration and Nationality Act by routinely discriminating against certain non-U.S. citizens working for the company. The settlement with Gap resolves claims that the company discriminated against certain non-U.S. citizens - including lawful permanent residents, refugees and asylees - and naturalized U.S. citizens because of their current or prior immigration status. The department found that Gap discriminated against workers by re-verifying their permission to work, even though there was no legal reason to do so. The department also determined that Gap discriminated against some non-U.S. citizens because of their immigration status by requesting that they provide specific documents to confirm that they still had permission to work. The department concluded that Gap's reliance on an electronic human resource management system - which had electronic Form I-9 functions - contributed to the company's discriminatory conduct. As part of the settlement, Gap will pay $73,263 in civil penalties, provide back wages to an asylee and a lawful permanent resident who lost work because of Gap's practices, train thousands of its employees nationwide, ensure that its electronic programs are compliant with applicable rules, and be subject to monitoring and reporting requirements. The INA prohibits employers from unnecessarily re-verifying a worker's permission to work, or specifying the types of documentation a worker is allowed to show to prove permission to work, because of the worker's citizenship, immigration status or national origin. As a result, even when an employer has a legal requirement to check that a worker still has permission to work, the employer must allow the worker to present whichever acceptable documentation the worker chooses.Reference Link

14:55 EST Olema Pharmaceuticals trading halted, volatility trading pause

14:42 EST Novavax trading resumes

13:47 EST Kraft Heinz completes sale of natural cheese business for $3.3B - The Kraft Heinz Company announced that it has completed the sale of certain assets in its global cheese business and the license of certain trademarks to an affiliate of Groupe Lactalis for total consideration of approximately $3.3B, including cash consideration of approximately $3.2B. The transaction involves the divestiture of Kraft Heinz's natural, grated, cultured, and specialty cheese businesses in the U.S., its grated cheese business in Canada, and its grated, processed, and natural cheese businesses outside the U.S. and Canada. This divestiture includes the Company's global intellectual property rights to several brands, including, among others, Cracker Barrel, Breakstone's, Knudsen, Athenos, Polly-O, and Hoffman's, as well as the Cheez Whiz brand in the majority of countries outside the U.S. and Canada. The transaction also includes perpetual licenses for the Kraft and Velveeta brands that the Company will grant to Groupe Lactalis for certain cheese products. Kraft Heinz will retain its Kraft Singles, Velveeta processed cheese, and Cheez Whiz processed cheese businesses in the U.S. and Canada and its Kraft, Velveeta, and Cracker Barrel macaroni and cheese, Kraft sauces, and cream cheese, including Philadelphia cream cheese, businesses worldwide.

13:13 EST Lundin says 'no conclusive decisions' on potential value opportunities - Lundin Energy "has noted recent speculation in the markets." It said in a statement: "The Company continuously engages in opportunities that are potentially value accretive to its shareholders. In that context, the Company does at times hold discussions with various parties. As of today there are no conclusive decisions that have been made in relation to any such discussions."

12:09 EST Vale trading resumes

12:01 EST Zynga enters multi-year partnership with pro rally driver Ken Block - Zynga announced that NaturalMotion is the official game partner of professional rally driver Ken Block, for the popular mobile drag racing game, CSR Racing 2. In the game, players collect and tune the hottest and latest cars to compete on tracks.

12:00 EST Sonendo falls -11.2% - Sonendo is down -11.2%, or -$1.29 to $10.21.

12:00 EST R.R. Donnelley rises 9.9% - R.R. Donnelley is up 9.9%, or 92c to $10.21.

12:00 EST Lithium Americas rises 12.4% - Lithium Americas is up 12.4%, or $4.41 to $40.10.

11:46 EST Valneva announces collaboration for production of inactivated COVID-19 vaccine - Valneva SE and IDT Biologika announced their collaboration for the production of Valneva's inactivated COVID-19 vaccine candidate VLA2001. This follows last week's announcement that Valneva signed an advance purchase agreement with the European Commission to supply up to 60 million doses of VLA2001, over two years, the company noted. Under the collaboration, IDT Biologika will produce VLA2001's drug substance at its Biosafety Level 3 facilities in Dessau-Rosslau, Germany, in addition to Valneva's manufacturing site in Livingston, Scotland. Thomas Lingelbach, CEO of Valneva, commented, "IDT is a well-established partner within Valneva's manufacturing network. As such we are extremely pleased to extend this partnership to supply VLA2001. This collaboration will help ensure our inactivated vaccine is available for rapid deployment as we continue to believe that our differentiated vaccine candidate can make an important contribution to the global fight against the COVID-19 pandemic."

11:34 EST Biofrontera Inc trading halted, volatility trading pause

11:20 EST Vale trading halted, news pending

11:00 EST Twitter resumes trading after CEO change, shares up 5% to $49.27

10:45 EST Jack Dorsey to remain on Twitter board until term expires in 2022

10:40 EST Twitter announces Jack Dorsey steps down, names Parag Agrawal CEO

10:26 EST Biofrontera Inc trading resumes

10:03 EST Nuvei approved to provide payment processing to sports wagering operators - Nuvei Corporation has announced that its wholly-owned subsidiary has been granted permission to provide payment processing services to daily fantasy sports and sports wagering operators in Louisiana. The approval by the Louisiana Gaming Control Board enables the Company to support online sports betting across the state.

10:00 EST Natuzzi falls -8.7% - Natuzzi is down -8.7%, or -$1.48 to $15.52.

10:00 EST Ambrx Biopharma rises 8.7% - Ambrx Biopharma is up 8.7%, or 94c to $11.74.

10:00 EST R.R. Donnelley rises 9.8% - R.R. Donnelley is up 9.8%, or 91c to $10.20.

09:48 EST Scholastic names Mary Beech as Chief Marketing & Transformation Officer - Scholastic announced Mary Beech has been named Scholastic's Chief Marketing & Transformation Officer, effective January 1, 2022. Beech, who has been an independent director on Scholastic's Board since 2018, will resign from the board in advance of her new position, which reports directly to CEO and President Peter Warwick. In the new role for the company, Beech "will be charged with creating greater customer centricity, data-driven activations with a focus on digital, and connectivity throughout Scholastic to better serve educators, caregivers and children," the company said. Beech has most recently served as the CEO of Sarah Flint, a direct-to-consumer, luxury footwear brand for women.

09:47 EST Scor ADR falls -10.2% - Scor ADR is down -10.2%, or -$1.64 to $14.34.

09:47 EST R.R. Donnelley rises 9.9% - R.R. Donnelley is up 9.9%, or 92c to $10.21.

09:47 EST Callon Petroleum rises 11.2% - Callon Petroleum is up 11.2%, or $5.77 to $57.25.

09:41 EST Adagio Therapeutics Inc trading resumes

09:35 EST Save Foods reports first commercial sale of PeroSTAR - Save Foods announced the first commercial sales of its PeroSTAR product to two of the leading bell pepper packing houses in Israel's Arava region. After their positive experience trying Save Foods' treatment, the packing houses decided to fully integrate the Company's product in their treatment process to ensure the optimal quality and shelf life of their bell peppers. The Arava region produces approximately 60% of all of the fresh vegetables that Israel exports, and bell peppers are the leading crop, largely sold to Russia, North America, and the UK. This first commercial sale for the treatment of bell peppers in Israel comes on the heels of the Company's recent regulatory approval of its product by the California Department of Pesticide Regulation. That CDPR approval also covers bell peppers, a crop valued at $479 million in the United States, with California accounting for nearly 50% of peppers grown in that market.

09:32 EST CIT Group served as coordinating lead arranger on $210M financing for project - CIT Group announced that its Power and Energy business served as coordinating lead arranger on $210M in financing for a solar project in Brazoria County, Texas. Located in the Greater Houston power market Brazoria West Solar Project is a utility-scale solar project with 260 megawatts of direct current generation capacity. Construction is underway, with commercial operation planned for 2022. The project was developed by Savion, an affiliate of Macquarie's Green Investment Group. Immediately upon closing, the project was sold to and the debt assumed by S&B US Energy, subsidiary of Shikun & Binui, a global Israeli infrastructure and real estate company. S&B US Energy will take over the development from closing through commercial operations. "Savion and the Green Investment Group are renowned for their expertise in the power generation space and we are pleased to collaborate with them to support their financing needs on this project," said Mike Lorusso, managing director and group head for CIT's Power and Energy business. "We are equally excited to help Shikun & Binui establish a foothold in the U.S. power and infrastructure markets as they continue to grow their portfolio here."

09:28 EST Euroseas announces charter contracts for M/V Synergy Oakland - Euroseas announced two new consecutive time charter contracts for its container vessel M/V "Synergy Oakland", a 4,253 TEU vessel built in 2009. Specifically: a new time charter contract for a period of between two and three months at a daily rate of $130,000, commencing between January 5th and January 25th when the vessel will be redelivered from its current charterer; and, immediately following the completion of the above charter, a new time charter contract for a period of a minimum of forty-eight and a maximum of fifty-one months at the option of the charterer at a daily rate of $42,000, commencing the latest by April 15th when the vessel will be redelivered from its previous charterer.

09:28 EST Twitter soars after CNBC says Jack Dorsey stepping down - Shares of Twitter (TWTR) are moving higher after CNBC's David Faber reported that its CEO Jack Dorsey will be stepping down from his executive role. Faber cited sources for the news. Twitter in premarket trading is up 11% to $52.13 while Square, where Dorsey is also CEO, is up 3% to $219.40. Reference Link

09:26 EST Medigus says Jeffs' Brands submits confidential draft registration statement - Medigus announced that its 50.03% owned subsidiary, Jeffs' Brands Ltd., a data-driven e-commerce company operating on the Amazon Marketplace, confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to a potential initial public offering of its ordinary shares in the United States. The timing, number of ordinary shares to be offered and the price range for the proposed offering have not yet been determined.

09:23 EST Hyundai Motor partners with Siemens for digital mobility transformation - Siemens and Hyundai Motor Company and Kia Corporation announced a new technology partnership to accelerate their digital transformation and a new future of mobility-Hyundai and Kia has selected Siemens as the preferred bidder and strategic partner to provide next generation engineering and product data management through NX software and the Teamcenter portfolio from Siemens' Xcelerator portfolio of integrated software, services and development platform. Hyundai and Kia has evaluated and assessed various alternatives including incumbent solutions and selected Siemens' software.

09:22 EST TRC amends offer for Zillow Group - TRC Capital Investment Corporation announced that in view of current financial market conditions, TRC has amended the terms of its tender offer for up to 2,000,000 shares of Class C Capital Stock of Zillow Group and has decreased the offer price payable to US$55.00 per share from $61.20 per share. TRC also announced that its offer will still expire at 12:01 a.m. New York City time on December 15, 2021, unless further extended. As of close of business on Friday, November 26, 2021, no shares had been tendered. TRC will accept for payment and will pay for all shares validly tendered prior to the expiration date and not properly withdrawn in accordance with the terms of the offer. TRC will not be required to accept for payment or pay for any shares and may terminate the offer if certain conditions which, in the reasonable judgment of TRC in any such case, makes it inadvisable to proceed with the offer or with such acceptance for payment or payment. Stockholders of the Company who have already tendered their shares and have not withdrawn such shares need not take any additional action with respect to TRC's amended tender offer. These stockholders will receive the decreased offer price of US$55.00 per share in TRC's tender offer. TRC has amended its tender offer materials to reflect the decreased offer price and other relevant changes.

09:20 EST Fastly announces Lakshmi Sharma as new Chief Product Officer - Fastly (FSLY) announced Lakshmi Sharma as its new Chief Product Officer, effective November 29, . Sharma brings more than 20 years of engineering and product development experience to Fastly and will spearhead the company's continued investment in products that enable developers to build modern, distributed applications and digital experiences that maximize performance, programmability, and security. Sharma has been building dynamic product organizations for decades, having most recently served as the Director of Product Management for Networking at Google Cloud (GOOG), where the end-to-end customer experience for network solutions crossing multiple industries was a key responsibility. With extensive experience across infrastructure, cloud, and security organizations, including product and engineering leadership roles at Target Corporation, Cisco, and Juniper Networks, she is poised to make significant contributions to Fastly's delivery, security, and edge compute portfolio. Sharma will report directly to Fastly CEO Joshua Bixby and will focus on the long-term product roadmap and innovation that empowers Fastly customers to develop, deliver, and secure modern distributed applications.

09:16 EST Adial Pharmaceuticals announces preclinical data for PNV2 - Adial Pharmaceuticals announced positive pre-clinical data for PNV2 in an animal model of triple negative breast cancer. Based on the strength of this data, Purnovate, Inc., a wholly owned subsidiary of Adial Pharmaceuticals, Inc., plans to advance PNV2 as the lead compound for its cancer program. PNV2 was tested in a metastatic breast cancer model with the primary endpoint being the amount of cancer metastases into the lungs after 28 days following orthotopic implantation of breast cancer. Study highlights: Luciferase-engineered triple-negative breast cancer cells MDA-MB-231 were implanted in the mammary fat pad in female mice. Tumors grew over 28 days and were treated intratumorally three times a week. An active group was treated with PNV2 in solution and a control group (n=10) was treated with only the solution. Metastasis into the lungs was then determined by measuring the amount of luciferase activity, which indicates the amount of cancer in the lungs. In the control group, 30% of the mice had large, well-established secondary tumors in their lungs with luciferase activity of greater than 1585 AU in each mouse, while the PNV2 group appeared to have no large secondary tumors in the lungs of any mouse and luciferase activity of not more than 356 AU in any mouse. PNV2 has been tested to be more than 1000-fold selective over the adenosine A1 receptor, which is known to have cardiovascular and central nervous system effects that have limited the usefulness of adenosine analogs as treatments. Historically, when selectivity has been achieved over the A1 receptor, water solubility has decreased, making effective tissue distribution in the human body difficult to achieve. However, PNV2 has demonstrated solubility more than 50 times greater than other known selective adenosine compounds of the same class. Solubility is often an important characteristic of successful drug candidates, and Purnovate believes solubility is a particularly important characteristic in determining the drug development potential of molecules of this class.

09:14 EST Diebold 's DN Series ATMs deployed by Piraeus Bank - Piraeus Bank, a Greek multinational financial services company, is the first bank in the country to widely adopt automatic cash recycling by deploying more than 300 DN Series ATMs from Diebold Nixdorf. By upgrading to the industry's latest self-service technology, Piraeus Bank will support its commitment to sustainability as the DN Series will significantly reduce power consumption and CO2 emissions during the ATMs' life span. The DN Series family is made of recycled and recyclable materials and is 25% lighter than most traditional ATMs. This reduces CO2 emissions, both in the manufacturing and transportation of components and terminals. The cash recycling technology reduces cash-in-transit costs, which also minimizes carbon emissions. In addition, all DN Series ATMs use state-of-the-art LED technology and highly efficient electrical systems, resulting in up to 50% power savings versus traditional ATMs.

09:12 EST Martin Resource Management announces Alinda Capital/Senterfitt transaction - Martin Resource Management Corporation which through its wholly owned subsidiary owns a 51% voting interest n MMGP Holding , the sole owner of Martin Midstream which is the general partner of Martin Midstream Partners announced today that Senterfitt Holdings indirectly acquired the 49% voting interest in Holdings owned by certain affiliated investment funds managed by Alinda Capital Partners by purchasing certain entities from Alinda. Senterfitt is a privately held investment entity owned by Ruben S. Martin, III, President and Chief Executive Officer of MRMC. "I am pleased to have the opportunity to simplify the structure of the General Partner and to consolidate control back under the Martin umbrella," said Mr. Martin, "and in doing so show my personal commitment and support to MMLP and its management team." As part of the announced transaction, Martin Resource , a wholly-owned subsidiary of MRMC, has entered into call option agreements with the Senterfitt subsidiaries, which own the membership interest in Holdings. Subject to certain conditions, MRLLC will have the right, but not the obligation, to purchase all of the membership interests of Holdings owned by such subsidiaries for a period of ten years. At closing, the General Partner amended and restated its limited liability company agreement to revise corporate governance procedures and eliminate Alinda's preferential right with respect to the board appointment process, which had expanded the Board of Directors of the General Partner to seven members and provided Alinda with the preferential right to appoint three members. The elimination of the preferential right results in the reduction of the Board to five members, at least three of which are required to be independent in accordance with SEC and NASDAQ requirements. Upon closing, Holdings reappointed Ruben S. Martin, III, Robert D. Bondurant, Byron Kelley, C. Scott Massey and James Collingsworth to serve on the Board.

09:12 EST Sorrento Therapeutics publishes abivertinib teaser - Sorrento Therapeutics announced the publication of a Teaser titled "Abivertinib - a Franchise Oral Therapeutic for Cancer, COVID-19 and Autoimmune Diseases". Sorrento intends to use the Abivertinib Teaser to engage in discussions with interested third parties in the pharmaceutical industry. The key highlights of the Abivertinib Teaser are outlined below. Abivertinib for COVID-19: 100 mg once-a-day oral capsule for hospitalized COVID-19 patients: US trial and Brazil trial: For Severe Ordinal Scale Category 5 COVID-19 Patients identified to be beneficial with Abivertinib treatment at Day 28: Abivertinib reduced the risk of death or respiratory failure: by 48% in US trial; by 45% in Brazil trial. Abivertinib reduced the ICU stay: by 2 days in the US trial. Abivertinib for Cancer Indications: NSCLC - Among 209 response evaluable NSCLC patients who developed resistance to first line Tyrosine Kinase Inhibitors: 93.3% subjects achieved tumor shrinkage at target lesions; 57.4% subjects achieved the best ORR; 52.2% subjects achieved confirmed PR; 24.9 months OS,B-Cell Lymphoma: 63.6% ORR; 95.5% DCR; 19.7 Months PFS. Abivertinib - A Broad Pipeline for Cancer, COVID-19 and Autoimmune Diseases.

09:10 EST MicroStrategy sold 571,001 shares to buy 7,002 bitcoins over last two months - MicroStrategy announced that between October 1 and November 29, it purchased 7,002 bitcoins for $414.4M in cash, at an average price of approximately $59,187 per bitcoin, inclusive of fees and expenses. As of November 29, MicroStrategy holds 121,044 bitcoins that were acquired at an aggregate purchase price of $3.57B and an average purchase price of approximately $29,534 per bitcoin, inclusive of fees and expenses. As previously disclosed on June 14, the company entered into an open market sale agreement with Jefferies, pursuant to which the company may issue and sell shares of its class A common stock, having an aggregate offering price of up to $1B from time to time. Between October 1 and November 29, MicroStrategy had issued and sold an aggregate of 571,001 shares under the sale agreement, at an average gross price per share of $732.16, for aggregate net proceeds of $414.4M.

09:08 EST Seelos Therapeutics enters exclusive license agreement with iX Biopharma - iX Biopharma announced today that it has, through its subsidiary, entered into an exclusive license agreement with Seelos Therapeutics. Under the agreement, iX Biopharma will license to Seelos its lead drug under development, Wafermine, a sublingual racemic ketamine wafer, and other products incorporating R- and S- enantiomers of ketamine utilising the WaferiX technology. iX Biopharma will receive a $9M upfront payment to be satisfied in cash and shares. iX Biopharma is also eligible for up to $239M in milestone payments upon achievement by Seelos of certain development milestones and product sales thresholds. iX Biopharma will also receive double digit royalties on future net sales of any Licensed Product. Seelos will fund all future development, manufacturing and commercialisation of the Licensed Products. "The licensing of the WaferiX drug delivery platform for sublingual ketamine broadens Seelos' ketamine franchise with formulations that we believe will be suitable for both acute and chronic dosing. This should enable us to study additional indications beyond our current focus," said Raj Mehra, Ph.D., Chairman and CEO of Seelos. "The pharmacokinetics, pharmacodynamics and safety profile that has been demonstrated to date suggests a formulation that has the potential of being prescribed with less restrictions than current formulations. Our team is excited to be able to study additional indications with this very innovative technology." Under the terms of the agreement, Seelos will have exclusive worldwide rights for Wafermine except China, and worldwide rights to products incorporating R- and S- enantiomers of ketamine being developed using iX Biopharma's WaferiX technology. iX Biopharma will retain exclusive rights to Wafermine in China.

09:07 EST Nuance launches AI-powered Precision Imaging Network - Nuance Communications launched the Nuance Precision Imaging Network, an AI-powered cloud platform that delivers patient-specific data and insights from diagnostic imaging into existing clinical and administrative workflows across the healthcare ecosystem. The Nuance Precision Imaging Network connects imaging stakeholders and facilitates the use of AI to inform precision diagnostics and therapeutics, increase physician efficiency, and lower overall healthcare costs. "Nuance recognizes that almost every patient story starts with a diagnostic image. The Nuance Precision Imaging Network is the only nationwide patient-centered diagnostic imaging platform that seamlessly delivers AI-generated patient information into the full array of clinical and administrative workflows across provider, payer, and life science use cases," said Peter Durlach, Chief Strategy Officer, Nuance. "By leveraging Nuance's unmatched scale in diagnostic imaging built up over the past 25 years and a robust partner ecosystem, the Nuance Precision Imaging Network establishes a common cloud-based framework that enables all stakeholders to apply rapid advances in imaging AI to improve clinical outcomes, financial performance, and efficiency across the entire patient journey from screening through follow-up."

09:05 EST Hims & Hers partners with Uber for on-demand delivery - Hims & Hers (HIMS) announced its largest on-demand delivery partnership with Uber Technologies (UBER), to bring a wide array of the company's personal care products to customers through the Uber Eats app. Starting immediately, customers in Los Angeles, San Francisco, Sacramento, Miami, Houston, Austin, Dallas, San Antonio, Philadelphia, Seattle, Atlanta and Phoenix will be able to access Hims & Hers products through the Uber Eats app, with plans for expansion into new markets on the horizon.

09:04 EST Qualys cloud agent achieves AWS Graviton Ready designation - Qualys (QLYS) announced it achieved the AWS Graviton Ready designation, part of the Amazon (AMZN) Web Services, AWS, Service Ready Program. This designation recognizes the successful integration of the Qualys Cloud Agent with AWS Graviton Service. The new integration allows joint customers to take use AWS Graviton2 ARM architecture while leveraging Qualys' Cloud Platform to secure their critical assets with a single IT, security, and compliance platform. Using the Qualys Cloud Agent, customers can activate multiple Qualys applications. "Qualys is proud to build on its history of innovation and to work with AWS on its next-generation Graviton2 processor," said Sumedh Thakar, president and CEO of Qualys. "Our customers leverage the Qualys Cloud Platform to prevent, detect, and remediate cyber threats across their enterprise. Now they can achieve their security and compliance goals while benefitting from the cost efficiency and performance of modern infrastructure like AWS Graviton".

08:58 EST Johnson & Johnson pursuing omicron-specific variant vaccine - Johnson & Johnson said in a statement: "In collaboration with academic groups in South Africa and around the world, the Company has been evaluating the effectiveness of its COVID-19 vaccine across variants, including now the new and rapidly spreading Omicron variant. The Company is testing blood serum from participants in completed and ongoing booster studies to look for neutralizing activity against the Omicron variant. In addition, the Company is pursuing an Omicron-specific variant vaccine and will progress it as needed." Reference Link

08:56 EST iBio announces update for IBIO-202 program in light of Omicron variant - iBio announced an update for its lead COVID-19 vaccine program, IBIO-202, in light of the emergence of the Omicron variant of SARS-CoV-2. On November 26, 2021, the World Health Organization's Technical Advisory Group on SARS-CoV-2 Virus Evolution classified Omicron as a Variant of Concern. According to the WHO, the Omicron variant has at least 30 mutations in the spike protein, which has been the target of first-generation COVID-19 vaccines. The Company believes that the N protein represents an important target for next-generation COVID-19 vaccines for several reasons. First, the N protein is abundantly expressed during infection and contains multiple immunogenic epitopes. Second, the N protein is more highly conserved than the S protein, and therefore, new variants may be less likely to escape vaccine protection. Third, research has shown that the N protein appears to be significantly more effective than the S protein in stimulating antibody-dependent natural killer cell activation, a critical element of the adaptive immune response that the SARS-CoV-2 virus attempts to evade

08:54 EST Entourage Health launches cannabis-infused soft chews for Starseed line - Entourage Health is pleased to announce it has entered into a commercial arrangement with Olli Brands Inc. to produce a suite of cannabis soft chews for sale under the Company's Starseed Medicinal brand. Product availability is expected to commence on November 30, 2021. The edible cannabis products will be available in CBD, THC and 1:1 soft chews for exclusive, initial release in two-unit packages, via Entourage's medical channel, Starseed Medicinal in the following flavours: strawberry-elderberry, pineapple-tangerine, and lemon-lime. Entourage recently completed R&D trials alongside OBi, producing multiple product formulations that yielded strong and favourable results which could provide additional product expansion opportunities. Obi is a highly skilled, third-party, white-label processor widely recognized in Canada for consistently and safely producing premium edible cannabis products. OBi operates from its sophisticated manufacturing facility in Etobicoke, Ontario.

08:50 EST BioCryst begins patient enrollment in REDEEM-2 trial of BCX9930 - BioCryst announced the enrollment of the first patient in the REDEEM-2 pivotal trial with its oral Factor D inhibitor, BCX9930, in patients with paroxysmal nocturnal hemoglobinuria. REDEEM-2 is a randomized, placebo-controlled trial evaluating the efficacy and safety of BCX9930 as monotherapy versus placebo in approximately 57 PNH patients not currently receiving complement inhibitor therapy. In part 1 of this trial, patients will be randomized 2:1 to receive BCX9930 or placebo under double-blind conditions for 12 weeks. All patients will receive BCX9930 in part 2 to assess the long-term safety, tolerability and effectiveness of BCX9930, with patients randomized to placebo in part 1 switching to BCX9930 at the week 12 visit. The primary endpoint of REDEEM-2 is change from baseline in hemoglobin, as assessed at week 12. REDEEM-2 is powered at 90 percent to detect a difference in mean change from baseline of hemoglobin of greater than or equal to 2.15 g/dL at 12 weeks. In a dose-ranging trial of BCX9930 in treatment-naive patients, the company previously reported that BCX9930 increased hemoglobin from baseline by a mean of 3.7 g/dL at week 12 and eliminated transfusions. BCX9930 was safe and generally well-tolerated in the trial. BioCryst also is preparing to enroll patients in the REDEEM-1 pivotal trial, a randomized, open-label, active, comparator-controlled comparison of the efficacy and safety of BCX9930 monotherapy in approximately 81 PNH patients with an inadequate response to a C5 inhibitor. Additionally, the company is initiating a proof-of-concept trial of BCX9930 in renal complement-mediated diseases. The U.S. Food and Drug Administration has granted both Fast Track status and Orphan Drug Designation to BCX9930 for PNH.

08:49 EST Celsion to present poster at Cytokine-Based Cancer Immunotherapies Summit - Celsion Corporation announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be making a presentation on the Company's GEN-1 interleukin 12 immunotherapy program at the Cytokine-Based Cancer Immunotherapies Summit being held in Boston on November 30 to December 2, 2021. Dr. Anwer's presentation, titled "A Non-Viral Gene Therapy Approach to IL-12 Delivery for The Treatment of Cancer," will be delivered on December 2 at 8:10 a.m. Eastern time. The Company was invited to submit a poster presentation which aligns with Dr. Anwer's oral presentation on the GEN-1 IL-12 program. The poster presentation will contain a subset of his presentation slides. Dr. Anwer will also be participating in two panel discussions. In his presentation, Dr. Anwer will be discussing how local delivery of IL-12 without significant systemic toxicity is feasible with a non-viral gene therapy approach that involves administration of an IL-12 plasmid with a synthetic DNA delivery system. Dr. Anwer will also be discussing how weekly intraperitoneal administration of GEN-1 yields durable increases in IL-12 and IFN-, and why repeated weekly administration of GEN-1 in combination with standard chemotherapy remodels the tumor immune environment to favor immune stimulation over immune suppression.

08:47 EST Harbor Custom Development enters commitment with Broadmark Realty Capital - Harbor Custom Development (HCDI) announced that it has entered into a preliminary commitment for $19,129,000 in construction financing with Broadmark Realty Capital (BRMK) for 126 units of the first phase of Harbor's 228-unit Apartment complex located in Belfair, Washington. Located in the town of Belfair in North Mason County, the 228-unit apartment project currently under construction is conveniently situated adjacent to highway SR 3 and provides views of the Puget Sound and the Olympic Mountains. Belfair is approximately a 15-minute drive to downtown Bremerton, the Seattle ferry, and the Kitsap Naval Base, a major contributor to a robust defense economy with approximately 40,000 employees tied to the military and defense industry in the area.

08:44 EST Lantheus announces availability of PYLARIFY AI - Lantheus Holdings announced that PYLARIFY AI, its recently FDA-cleared medical device software, is now commercially available in the United States. PYLARIFY AI employs a deep learning algorithm that has been trained and validated across more than 3,000 images to allow healthcare professionals and researchers to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. Through rigorous analytical and clinical studies, PYLARIFY AI has demonstrated improved consistency, accuracy and efficiency in quantitative assessment of PSMA PET/CT. PYLARIFY AI can be deployed either as a secure web cloud application or within the secure firewall of the institution on a local server. Once deployed, the adaptive application can be integrated into an institution's existing clinical workflow, delivering a unique combination of clinical utility and technical flexibility. Syntermed, a leading provider of nuclear imaging software, has been appointed as the first distributor of PYLARIFY AI for the U.S.

08:42 EST Reliance Global announces launch of 5MinuteInsure.com in four states - Reliance Global Group announced that it has launched 5MinuteInsure.com in Missouri, Alabama, Iowa and West Virginia.

08:38 EST Chegg to acquire Busuu for $436M in an all-cash transaction - Chegg announced that it has entered into a definitive agreement to acquire Busuu, a language learning platform which has reached over 120M learners to date across more than 160 countries. Busuu provides courses in 12 different languages to over 500,000 paying subscribers. Founded in 2008 by Bernhard Niesner and Adrian Hilti, with offices in London, UK, and Madrid, Spain, Busuu has established a community for language learning, with over 20,000 new registrations daily. Chegg expects Busuu's FY21 revenue to be approximately $45M with year-over-year growth of greater than 20%. Chegg expects to acquire Busuu for approximately $436M in an all-cash transaction subject to the terms and conditions of the definitive agreement. The acquisition, which was approved by the boards of directors of Chegg and Busuu, is expected to close early in Q1 of 2022, subject to customary closing conditions.

08:37 EST RegeneRx join venture requests pre-BLDA meeting with FDA for RGN-259 - RegeneRx Biopharmaceuticals announced that its U.S. joint venture, ReGenTree, has submitted a letter to the U.S. FDA requesting a pre-BLA meeting pursuant to RGN-259, its novel product candidate for dry eye syndrome. The purpose of a pre-BLA meeting is to discuss with FDA the format, content, and acceptability of the anticipated BLA application. As previously reported, ReGenTree has been working with two third-party FDA consulting firms prior to requesting the pre-BLA meeting. This includes a review of clinical studies, non-clinical studies, CMC requirements, and previous meeting minutes between RegeneRx, ReGenTree and FDA. "I am pleased ReGenTree has submitted the pre-BLA request to FDA regarding RGN-259, which is based on our results to date and on FDA's draft development guidelines for dry eye syndrome established in December of 2020. We expect to know in the next few weeks if the FDA agrees with our meeting proposal and look forward to receiving their comments regarding a number of questions/clarifications typical in such requests. If all goes well, we expect to meet with the Agency around the end of January 2022. We look forward to keeping our investors apprised of our progress along the way," stated J.J. Finkelstein, RegeneRx president and chief executive officer. ReGenTree, LLC is a U.S. joint venture owned by HLB Therapeutics and RegeneRx Biopharmaceuticals, Inc. ReGenTree.

08:36 EST Capital Power, Enbridge collaborate to reduce CO2 emissions in Alberta - Capital Power Corporation (CPXWF) and Enbridge Inc. (ENB) are pleased to announce a memorandum of understanding to collaborate on carbon capture and storage solutions in the Wabamun area west of Edmonton, Alberta, near Capital Power's Genesee Generating Station. Enbridge and Capital Power have agreed to jointly evaluate and advance a CCS project, with Enbridge as the transportation and storage service provider and Capital Power as the CO2 provider, subject to the Government of Alberta's competitive carbon hub selection process and a future final investment decision. Enbridge, with the support of Capital Power, is applying to develop an open access carbon hub in the Wabamun area through the Government of Alberta's Request for Full Project Proposals process, which is expected to start as early as December 2021. The proposed project would serve Capital Power's Genesee Generating Station near Warburg, Alberta which currently provides over 1,200 megawatts of baseload electricity generation to Albertans. Capital Power is currently repowering the Genesee 1 and 2 units, to create North America's most efficient natural gas combined cycle power generation units, positioning them to deliver reliable and affordable electricity for generations to come. The Genesee CCS Project is expected to capture up to 3 million tonnes of CO2 annually from the repowered units, which would be transported and stored through Enbridge's open access carbon hub that could also serve several other local industrial companies. Subject to the award of carbon sequestration rights and regulatory approvals, the proposed project could be in service as early as 2026.

08:35 EST American States Water announces settlement agreement in general rate case - American States Water announced that on November 23, its regulated water utility subsidiary, Golden State Water Company, or GSWC, and the Public Advocates Office at the California Public Utilities Commission, or CPUC, filed a joint motion to adopt a settlement agreement between GSWC and Cal Advocates in connection with the water utility general rate case. GSWC had filed a general rate case application in July 2020 for all of its water regions and the general office to determine new rates for the years 2022 - 2024. The CPUC is expected to issue a proposed decision in the water general rate case during the first half of 2022. When approved, the new rates are expected to become effective and retroactive to January 1, 2022. The proposed settlement agreement, if approved by the CPUC, resolves all issues related to the calculation of the 2022 annual revenue requirement in the general rate case application, leaving only three unresolved issues. Among other things, the settlement authorizes GSWC to invest approximately $416.6M in capital infrastructure over the three-year rate cycle in order to continue to provide safe and reliable water utility service to its customers. The $416.6M of infrastructure investment, as settled, includes $11.8M of capital projects to be filed for revenue recovery through advice letters when those projects are completed. Excluding the advice letter project revenues, under the terms of the settlement agreement GSWC's adopted operating revenues less water supply costs, or RLWSC, for 2022 increases by approximately $20.6 million as compared to the 2021 adopted RLWSC. The settlement agreement also allows for potential additional increases in adopted revenues of approximately $13M for each of the years 2023 and 2024 based on inflation factors used at the time of the application filing in July 2020. The increases in 2023 and 2024 are subject to the results of an earnings test and changes to the forecasted inflationary index values. Actual increases for 2023 and 2024 will be determined at the time the filings to implement the new rate increases are approved by the CPUC, and will be calculated using inflationary index values at that time.

08:34 EST CBAK Energy completes majority stake acquisition of Hitrans - CBAK Energy Technology announced that its wholly-owned subsidiary Dalian CBAK Power Battery has completed its previously announced acquisition of a majority stake in Zhejiang Hitrans Lithium Battery Technology, a lithium-ion battery material supplier in China formerly known as Zhejiang Meidu Hitrans Lithium Battery Technology. Upon closing of the transaction, CBAK Power is now the largest shareholder of Hitrans owning 81.56% of its equity. Hitrans has been selected as one of small and medium-sized enterprises that dominate major markets in niche sectors with a wide spectrum of government support like financial and tax incentives to propel them to further grow into "small giants." Yunfei Li, Chief Executive Officer of CBAK Energy commented," The closing of this deal heralds an exhilarating time of renewed opportunity for us. By building a tighter relationship with Hitrans, which has also been a critical supply chain partner of our Company, we believe this offers CBAK Energy a unique vantage point to cope with rising challenges from supply chain constraints in the short run. In the longer run, we hope this deal will unlock incredible potential for both companies to seize and tap into growing opportunities available in the burgeoning electric vehicle industry."

08:33 EST Dominion Lending Centres announces intention for substanstial issuer bid - Dominion Lending Centres announced its intention to commence a substantial issuer bid pursuant to which the Corporation will offer to purchase for cancellation up to 3,000,000 of its outstanding common shares at a purchase price of $3.75 per Share in cash. See "Source of Funds and New Credit Facilities" below for details on how the Corporation will fund the Offer. The closing price of the Shares on the TSX Venture Exchange on November 26, 2021, the last full trading day prior to the Corporation's announcement of its intention to make the Offer, was $3.35. The board of directors of the Corporation believes that the recent trading price of the Shares is not fully reflective of their intrinsic value based on the value of DLC's assets and its business and future prospects. Accordingly, the Board believes that the Offer is a prudent use of the Corporation's financial resources given the Corporation's business profile and assets, current market price of the Shares, capital availability and cash requirements. The Offer provides DLC with the opportunity to return up to $11.25 million of capital to Shareholders who elect to tender while at the same time increasing the proportionate Share ownership of Shareholders who elect not to tender. The Purchase Price represents a 14.7% premium over the 30-day volume weighted average closing price of the Shares on the TSX for the period ending on November 26, 2021, and a 11.9% premium over the closing price of the Shares on the TSX on November 26, 2021, the last full trading day prior to the Corporation's announcement of its intention to make this Offer. The number of Shares subject to the Offer represents approximately 6.5% of the total number of Shares outstanding. Details of the Offer, including instructions for tendering Shares to the Offer and the factors considered by the Board making its decision to approve the Offer, will be included in the formal offer to purchase and issuer bid circular and other related documents, which are expected to be mailed to shareholders and filed with applicable Canadian Securities Administrators on or about December 1, 2021 on SEDAR at www.sedar.com and on the Corporation's website at www.dlcg.ca. Shareholders should carefully read the Offer Documents prior to making a decision with respect to the Offer. The Offer will not be conditional on any minimum number of Shares being tendered but will be subject to various other conditions that are typical for a transaction of this nature. The Offer will expire at 5 p.m. Eastern time on January 11, 2022, unless terminated or extended by the Corporation. If more than 3,000,000 Shares are properly tendered to the Offer, the Corporation will take-up and pay for the tendered Shares on a pro-rata basis according to the number of Shares tendered, except that "odd lot" tenders will not be subject to pro-ration. Assuming that 3,000,000 Shares are purchased pursuant to the Offer, the aggregate purchase price pursuant to the Offer will be $11,250,000. The Board has authorized the making of the Offer. However, the Board is not making any recommendation to any Shareholders as to whether to tender or refrain from tendering their Shares under the Offer. Shareholders are strongly urged to consult their own financial, tax and legal advisors and to make their own decisions whether to tender or to refrain from tendering their Shares to the Offer and, if so, how many Shares to tender. The Corporation was authorized by the TSXV to purchase up to 2,332,697 Shares pursuant to a normal course issuer bid that commenced on January 18, 2021 and expires on January 17, 2022. Since January 18, 2021, the Corporation has purchased 296,100 Shares through the NCIB. There will be no further purchases of Shares under the NCIB until after the expiry of the Offer or date of termination of the Offer.

08:31 EST SmartBank scales presence in Nashville, Tennessee - SmartBank announced the hiring of three experienced banking professionals, commercial relationship managers, Rachael Meurrier and Tony Graves and regional mortgage production manager, Kent Stone. All three individuals are based in the Nashville, TN area and will focus on building greater market presence for SmartBank. Following the recent expansions throughout Alabama, the Gulf Coast and Florida Panhandle, the Company is pleased to continue its push into the Nashville and broader middle Tennessee market area with these seasoned individuals. Rachael Meurrier, formerly with Triumph Bank, will join SmartBank as Senior Vice President and Williamson County Market Executive. Meurrier brings over 15 years' experience in the private banking and commercial lending space and will be joined by Senior Vice President Tony Graves. Graves, formerly with Reliant Bank and First Advantage Bank, brings over 30 years' commercial banking experience. On the consumer banking side, Kent Stone, previously with Triumph Bank, joins as Regional Mortgage Production Manager and brings over 15 years' mortgage banking experience.

08:27 EST F-star Therapeutics to host virtual R&D day on December 6 - F-star Therapeutics announced that it will host an R&D Day webinar on Monday, December 6, 2021, from 8:00 a.m. to 10:00 a.m. ET. The Company will discuss F-star's bispecific antibody discovery platform that has led to significant value potential in our four proprietary clinical programs and over $2.2 billion in potential remaining milestone payments from licensing partnerships. The meeting will be hosted by F-star's scientific leadership, including Eliot Forster, Ph.D., CEO & President, Neil Brewis, Ph.D., Chief Scientific Officer, and Professor Florian Ruker, Ph.D., Co-Founder. Following a discussion of F-star's R&D platform, Louis Kayitalire, M.D., Chief Medical Officer, will present on the vast potential of the company's clinical pipeline of tetravalent mAb2 bispecifics, each of which is directed against some of the most exciting targets in immuno-oncology drug development, including LAG-3 and CD137.

08:25 EST Ultragenyx announces durability data from Phase 1/2 AAV gene therapy studies - Ultragenyx Pharmaceutical announced new long-term durability data from the Phase 1/2 studies of DTX401 for Glycogen Storage Disease Type Ia and DTX301 for Ornithine Transcarbamylase deficiency that were presented at the 14th International Congress of Inborn Errors of Metabolism. DTX401 for Glycogen Storage Disease Type Ia: Additional longer-term Phase 1/2 data presented at ICIEM 2021 demonstrate durability of response, with sustained responses lasting up to 3 years since treatment Across all 12 patients in the Phase 1/2 study, the mean reduction in daily cornstarch intake was 69.9% ranging from 19-100% when comparing baseline to the most recent visit. The nine patients in Cohorts 1, 2, and 3 continue to demonstrate improved glucose control while tapering or discontinuing oral glucose replacement therapy with cornstarch up to 3 years after receiving DTX401. The three patients in Cohort 4 have completed a tapering prophylactic steroid regimen. Two of the three patients have reduced the frequency of daily oral glucose replacement therapy from six times per day at baseline to one and two times per day as of their last visit. Across all patients in the Phase 1/2 study, to date there have been no infusion-related adverse events, no treatment-related serious adverse events, and no dose-limiting toxicities reported. DTX301 for Ornithine Transcarbamylase Deficiency: Additional longer-term Phase 1/2 data presented at ICIEM 2021 demonstrate durable metabolic control and sustained responses. The six patients who previously demonstrated a response remain clinically and metabolically stable, including all three treated at the highest dose, which is the dose that will be used in the Phase 3 study. The longest treated responders have demonstrated a durable response up to 4 years after dosing, and up to 3.5 years after discontinuing ammonia-scavenger medications and liberalizing protein-restricted diets. Two patients were enrolled into Cohort 4 of the DTX301 study and received a tapering prophylactic steroid regimen. Patient 10 is deemed a responder. As of the data cut-off, Patient 11 had completed the prophylactic steroid regimen and is in the process of modifying ammonia-scavenging drugs and or diet. Across all 11 patients in the Phase 1/2 study, to date there have been no infusion-related adverse events, no treatment-related serious adverse events and no dose-limiting toxicities reported. All treatment-related adverse events have been Grade 1 or 2, with the exception of one episode of grade 3 hyperammonemic crisis related to OTC deficiency.

08:22 EST Brooklyn ImmunoTherapeutics appoints Susan McClatchey as VP, head of quality - Brooklyn ImmunoTherapeutics announces the appointment of Susan McClatchey as Vice President, Head of Quality. Ms. McClatchey joins Brooklyn from IQVIA, a San Diego-based cell and gene therapy translation center.

08:22 EST Inhibikase Therapeutics announces publication on c-Abl - Inhibikase Therapeutics announced the publication of a paper describing the biochemical rationale and potential benefit of Abelson Tyrosine Kinase, c-Abl, inhibition as a potential disease-modifying therapy for Parkinson's Disease. The article, titled "Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity" was published online in the journal Movement Disorders on November 24, 2021. The publication analyzes the role of both c-Abl, a non-receptor tyrosine kinase, as well as misfolded alpha-synuclein in the initiation and progression of Parkinson's disease, PD. Therapeutic administration of IkT-148009, a highly selective c-Abl kinase inhibitor, demonstrated the ability to clear alpha-synuclein aggregates from the brain and GI tract, promote regeneration of neurons, and induce substantial functional recovery in measures of motor and non-motor function. These studies support that the inhibition of c-Abl could have disease modifying effects and further support the continued clinical development of IkT-148009. "Parkinson's disease affects an estimated one million people in the U.S. and remains a significant unmet medical need. Today's publication provides a detailed mechanistic understanding of the early steps in the disease process and the role c-Abl plays in neurodegeneration. Our lead candidate, IkT-148009, a selective c-Abl kinase inhibitor, has demonstrated the potential to halt and reverse disease progression in animal models," stated Milton H. Werner, Ph.D., President and Chief Executive Officer of Inhibikase Therapeutics and principal author of the manuscript published today along with co-author and Interim Chief Medical Officer Dr. Warren Olanow. "IkT-148009 is currently in a Phase 1b extension study in Parkinson's patients, which we believe will give us an early look into safety and tolerability of IkT-148009 in patients and evaluate potential improvements across motor and non-motor aspects of the disease in patients over 7-day dosing. We anticipate completing this extension study in 2022, and expect to present data from our Phase 1 and possibly Phase 1b studies at the AD-PD Meeting to be held March 15-20, 2022 in Barcelona, Spain."

08:20 EST Verve Therapeutics appoints Allison Dorval as CFOVoyager Therapeutics - Verve Therapeutics (VERV) announced that Allison Dorval has been appointed as chief financial officer. Ms. Dorval joins Verve from Voyager Therapeutics (VYGR) and brings more than 20 years of leadership experience in finance, accounting, financial reporting and investor relations.

08:19 EST iCAD announces data on ProFound AI at RSNA 2021 - iCAD announced new and real-world research demonstrating the value of ProFound AI for Digital Breast Tomosynthesis will be highlighted at the 107th Scientific Assembly and Annual Meeting of the Radiological Society of North America, November 28 - December 2. The Company is also showcasing its portfolio of world-class breast health solutions, including the latest versions of ProFound AI Risk and PowerLook Density Assessment, at McCormick Place in Chicago in the South Hall meeting suites 214-216. In a poster presentation titled "Use Of Artificial Intelligence Software To Identify Clinically Aggressive Lesions On Prior Digital Breast Tomosynthesis Exams Based On Molecular Subtypes," lead author Mary F. Ice, MD, radiologist at Rose Imaging Specialist and Solis Mammography, will discuss her research evaluating the use of ProFound AI in identifying and scoring lesions in prior DBT screening exams of cancer cases. Additionally, the following poster discussions will take place on Tuesday, November 30: "Effect Of Artificial Intelligence Software On Digital Breast Tomosynthesis Screening Cancer Detection And Abnormal Interpretation Rates Among Subspecialized Breast Radiologists: A Real-World Experience." Principal investigator Haley P. Letter, MD, Assistant Professor, Program Director of Breast Imaging and Intervention Fellowship and Associate Clerkship Director at University of Florida Health - Jacksonville, will present research from a real-world study assessing the impact of ProFound AI in DBT screening exams. "Tomosynthesis-driven AI-derived Breast Cancer Scoring Among A Racially Diverse Cohort Of Women Undergoing Screening: Potential For Triage And Precision Cancer Screening." Principal investigator Emily F. Conant, MD, professor and chief, Division of Breast Imaging at the Hospital of the University of Pennsylvania Medical Center, will discuss findings from an observational study evaluating ProFound AI and the impact of race on the software's performance and Case Scores.

08:17 EST Co-Diagnostics reports COVID-19 diagnostics not affected by Omicron mutations - Co-Diagnostics reported that none of the mutations in the heavily mutated SARS-CoV-2 variant recently discovered in Africa are predicted to interfere with any of the Company's suite of COVID-19 PCR diagnostic assays. The new coronavirus strain includes more than 50 mutations, over 30 of which are found on the virus's spike protein, the main target of the body's immune responses, and is currently being studied to determine whether the mutations lead to increased transmissibility or ability to evade the body's immune response. Co-Diagnostics successfully assessed the effectiveness of its existing line of COVID-19 PCR diagnostics against the Omicron variant using publicly available sequencing data in the GISAID database, and continues to monitor the performance of its tests as new variants are discovered. Dwight Egan, CEO of Co-Diagnostics, commented, "We are pleased to report that none of the over 50 mutations in this new variant are close enough to the targets of any of our COVID-19 diagnostics to interfere with their performance. This includes our original Logix Smart COVID-19 assay, first developed in the early days of news about the novel coronavirus being discovered in China, our SARS-CoV-2 2-gene test, our ABC multiplex assay, our COVID-19 extraction-free direct saliva test, and the test currently in development to be run on our upcoming at-home/point-of-care device."

08:16 EST H2O Innovation completes plant retrofit for ethanol client in Iowa - H2O Innovation announced that it has recently completed a plant retrofit for an ethanol client located in Iowa, United States. This project, one of the first of its kind in North America, demonstrates the Corporation's technical expertise and market access required to provide a direct replacement solution. Experience gained from this project should well-position H2O Innovation to support future market demand. H2O Innovation was awarded the contract for membrane replacement of the client's existing microfiltration of process water. The modules were approaching end of life based on reduced water flow and filtrate quality. The facility also needed to expand capacity without significant capital investment. The Corporation's solution, working closely with Toray Membrane USA, was to design the replacement around a new module that offers more surface area in the same footprint. H2O Innovation's engineering and field services capabilities and open-source strategy qualify the Corporation for this type of replacement. The Corporation estimates around 840 M gpm installed capacity of this type in North America will likely require replacement and upgrade in the next 5 to 10 years.

08:15 EST Harsco Environmental launches ecoproducts service line - Harsco Environmental announces it has launched ecoproducts - a new service line that includes 62 products serving seven industries, including iron and steel, road making and abrasives, roofing, construction and cement. Formerly named Applied Products, the new ecoproducts moniker better reflects Harsco Environmental's positive impact on the environment. ecoproducts(TM)strives to provide a sustainable alternative to virgin material by being more cost effective and offering higher performance than raw materials such as mined or processed metals.

08:13 EST Kratos Defense receives $4.1M unmanned aerial vehicle system award - Kratos Defense & Security Solutions announced that its Kratos Unmanned Systems Division has recently received a $4.1 million contract award from an international customer for high performance, unmanned aerial target drone system aircraft and related services. KUSD is a recognized industry leader in the design and production of affordable, high performance, jet powered, unmanned aerial aircraft and systems for threat representative target drones and tactical applications. Work under this contract award will be performed at secure Kratos manufacturing facilities and at customer locations. Due to competitive, security related, and other considerations, no additional information will be provided related to this contract award.

08:12 EST Capital Power, Endeavour to collaborate on CCS solutions in Alberta - Capital Power Corporation (CPXWF) and Enbridge (ENB) announce a memorandum of understanding to collaborate on carbon capture and storage, CCS, solutions in the Wabamun area west of Edmonton, Alberta, near Capital Power's Genesee Generating Station. Enbridge and Capital Power have agreed to jointly evaluate and advance a CCS project, with Enbridge as the transportation and storage service provider and Capital Power as the CO2 provider. Enbridge, with the support of Capital Power, is applying to develop an open access carbon hub in the Wabamun area through the Government of Alberta's Request for Full Project Proposals process, which is expected to start as early as December 2021. The proposed project would serve Capital Power's Genesee Generating Station near Warburg, Alberta which currently provides over 1,200 megawatts of baseload electricity generation to Albertans. The Genesee CCS Project is expected to capture up to 3Mtonnes of CO2 annually from the repowered units, which would be transported and stored through Enbridge's open access carbon hub that could also serve several other local industrial companies. Subject to the award of carbon sequestration rights and regulatory approvals, the proposed project could be in service as early as 2026.

08:09 EST SeaChange secures multi-million-dollar contract renewal with U.S. MSO - SeaChange International has secured a multi-year, multi-million-dollar contract renewal with one of the largest multiple-system-operators in the United States. SeaChange is uniquely positioned to service this customer as the Company's software solutions have helped this MSO manage content processing workflows at scale for over a decade to seamlessly ingest up to 350,000 video on demand assets annually. Under the renewed contract, SeaChange will provide premium support and services for the MSO to further streamline and optimize its content chain. This will include the automated orchestration of content workflows for VOD services and over the top platforms across multiple back-office systems that have distinct business and publication rules. SeaChange ensures the highest support quality for its customers by using containerized technology that allows for easily deployable operating system updates.

08:08 EST LiveVox partners with AppSmart, 'continues to build channel momentum' - LiveVox Holdings has announced a partnership with AppSmart the leading marketplace for businesses and technology advisors to find, buy and manage technology services. "The new partnership enables LiveVox to educate AppSmart's technology advisors on the benefits of its performance-driven, omnichannel contact center solutions - allowing LiveVox to reach an expanded customer-base. LiveVox provides businesses with a unified approach to delivering exceptional customer experiences by offering contact center solutions that are easy to implement and optimize. Under the terms of the agreement, 5,500+ AppSmart technology advisors will have access to all of LiveVox's cloud-based solutions to make them available to over 100,000 businesses in the AppSmart ecosystem. As a result, LiveVox will have the opportunity to grow its already extensive list of customers while showcasing its all-in-one solutions and differentiation next to peers and industry leaders," said the company in a statement. "AppSmart is the leading marketplace for B2B technology services and solutions with an expansive ecosystem of advisors and businesses that will help LiveVox continue to scale and expand our customer-base with the digital transformation tailwinds we are currently experiencing," said LiveVox CRO Erik Fowler. "This agreement is another crucial step in our continued commitment to channel growth - including hiring leading industry veterans and aligning ourselves with premier partners." The COVID-19 pandemic has changed the way many organizations are operating. With an increased emphasis on digital transformation and improved CX, LiveVox expects to see greater demand for cloud and the omnichannel engagement tools that contact centers need to meet customers where they are, in any environment.

08:07 EST 1847 Goedeker names Jody Rusnak as chief merchandising, brand innovation officer - 1847 Goedeker announced that it has appointed Jody Rusnak as chief merchandising and brand innovation officer. Rusnak will oversee the company's efforts related to customer acquisition, marketing, merchandising strategy and related areas. His start date is November 29. Rusnak was most recently a senior leader and the director of Appliances and Electronics at Nebraska Furniture Mart, which is a Berkshire Hathaway subsidiary.

08:06 EST Trulieve Cannabis issues first inaugural ESG report - Trulieve Cannabis announced the publication of its first Environmental, Social, and Governance, ESG, Report. The Report contains standard disclosures from the Global Reporting Initiative, GRI, Sustainability Reporting Standards, The Sustainability Accounting Standards Board, SASB, as well as the United Nations Sustainable Development Goals. The Report highlights ESG achievements to date and serves as a foundation for demonstrating how the Company's ESG approach, strategies and commitments are embedded within its core business. Key takeaways from the ESG report include: Conducted inaugural materiality assessment with an ESG consultant to identify and prioritize key non-financial topics; Formed a cross functional ESG Steering Committee; Established ESG targets for 2022; Reviewed Trulieve's environmental sustainability, approach to community engagement and social responsibility, and corporate governance protocols; and Discussed DEI initiatives

08:05 EST Celularity announces FDA clearance of IND application for CYNK-101 - Celularity announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for the use of CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients with first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction adenocarcinoma. CYNK-101 is an investigational genetically engineered natural killer cell therapy designed to enhance antibody-dependent cellular cytotoxicity with approved and novel antibody therapeutics. The Phase 1/2a open-label, non-randomized clinical trial is designed to evaluate the safety and preliminary efficacy of the combination treatment strategy.

08:04 EST Chembio Diagnostics receives SAHPRA approval for DPP SARS-CoV-2 Antigen Test - Chembio Diagnostics announced receipt on November 26, 2021, of South Africa Health Products Regulatory Authority approval for the DPP SARS-CoV-2 Antigen test, authorizing marketing and distribution of the test for use at the point-of-care by professional healthcare providers.

08:02 EST Athenex announces MAA for oral paclitaxel has been validated by UK MHRA - Athenex announced that its Marketing Authorization Application for oral paclitaxel and encequidar for the treatment of advanced breast cancer has been validated by the United Kingdom's Medicines and Healthcare products Regulatory Agency for review. The application qualifies for a 150 day assessment by which a decision on approvability of the product will be provided. A single pivotal Phase III study of Oral Paclitaxel served as the basis of the MAA. The study was a randomized, controlled clinical trial designed to compare the safety and efficacy of Oral Paclitaxel monotherapy versus IV paclitaxel monotherapy in patients with metastatic breast cancer. As previously reported, the study successfully achieved its primary endpoint showing statistically significant improvement in overall response rate, along with a lower incidence of neuropathy, for Oral Paclitaxel compared to IV paclitaxel.

07:49 EST Orchid Ventures sees path to revenue, profit growth in 2022 - The company said, "Management expects that their continued commitment and execution to their strategic priorities, driven by further developing and fine-tuning their product offerings and go-to-market strategies, will place them on a consistent path to revenue and profit growth in FY 2022. Efforts will continue to focus on creating differentiation with superior, high quality and safe products combined with leveraging new technologies and innovations to disrupt markets, attract more customers and build market share. The Company believes that the new business model and strategy will establish a more viable and attractive option for not just consumers, but for employees and investors as well."

07:47 EST Fury Gold Mines provides results for drill holes at Eau Claire project - Fury Gold Mines is pleased to provide results for six core drill holes at the Eau Claire project located in the Eeyou Istchee Territory in the James Bay region of Quebec. The drilling focused on demonstrating the potential to expand the deposit to the west on both the Hinge and Limb target areas. Drill hole 21EC-041 targeted the Hinge zone of the anticline that defines the geometry of the deposit and the interbedded magnesium and iron-rich basaltic units that host the majority of the resource. The drill hole intersected seven zones of mineralization over a 110-metre drill width, including 3.0 metres of 9.36 g/t gold, 3.0m of 3.38 g/t gold and 1.5m of 4.94 g/t gold. The multiple stacked zones of mineralization demonstrate that the deposit is open down plunge to the west and is situated approximately 100m below the defined resource at the deposit. Fury believes that the down plunge extension of the Eau Claire deposit has the potential to significantly expand the current resource. The Hinge target located to the west of the defined Eau Claire resource is defined by a 20- to 30-degree plunge of the anticline that defines the geometry of the deposit. The plunging anticline is interpreted to extend approximately one kilometre to the west based on geologic mapping and geophysical data that demonstrates a plunging conductivity anomaly that images the sediments hosted in the core of the fold. To date a total of four drill holes have tested the Hinge geometry of the Eau Claire anticline within the interbedded magnesium and iron rich basaltic units that host the bulk of the resource at the Eau Claire deposit. The results of these four drill holes demonstrates the potential to discover multiple stacked high-grade veins as evidenced by the 3m of 9.36 g/t gold and the previously announced intersection of 1m of 12.81 g/t in drill hole 21EC-032. Fury's technical team is currently planning the next series of drill holes into the Hinge zone with drill fences across the Hinge zone being planned on 50m to 100m step outs to the west. Seven drill holes targeted the direct extension of the 450-zone mineralization at the Limb target. All drill holes intersected stacked zones of quartz tourmaline veining proximal to quartz porphyry dykes that are consistent geologically with mineralization within the Eau Claire resource. Although no high-grade intercepts of mining width were encountered in the drilling the hydrothermal system remains open and the Company is further evaluating Limb targets further to the west. Complete drill results are presented below for both the Hinge and Limb targets. Fury's technical team views the results from the limited drilling completed to date at both the Hinge and the Limb targets as very encouraging. Every drill hole intersected quartz tourmaline veining consistent with what is observed at the Eau Claire deposit confirming that the mineralized system and more importantly the prospective interbedded magnesium and iron rich basalts remain open to the west. Drill hole 21EC-041 is the furthest west hole completed to date beneath the 850 zone, this hole has extended resource grade mineralization a further 100m to the west of Fury's previous drilling and 80m below previously identified mineralization at the 850 zone.

07:45 EST Sun Life Financial, CloudMD partner to expand Mental Health Coach services - The need to support Canadians and their mental health has never been greater. To help more people access care, Sun Life is expanding its partnership with CloudMD, the creators of Mental Health Coach. Following a successful seven-month pilot program, Sun Life will begin rolling out Mental Health Coach as part of its Group Benefits offering. Despite many Canadians experiencing mental health issues, a Sun Life study found over half are not seeking medical care. Cost, access, and feelings of embarrassment are the top barriers to blame. Sun Life and CloudMD are bridging the gap with Mental Health Coach. The service uses data analytics to identify Clients who are at risk of developing a mental health issue. It then proactively reaches out to guide Clients to the right resources and support. A Mental Health Coach team member meets virtually or by phone with the plan member. They walk the plan member through a mental health assessment and create a personalized plan based on the benefits available to them. The Mental Health Coach service monitors the plan members' progress and provides regular check-ins. They offer feedback and encouragement and can re-assess the plan member at any point in their journey. During the pilot, Sun Life worked closely with CloudMD to test and refine the Mental Health Coach service. Findings from the Mental Health Coach pilot include: 89% of those experiencing depression and 91% of those experiencing anxiety noticed 'major improvements'. 73% said they have a better understanding of their benefits. 82% said they would recommend the service based on their own experience. 46% increase in plan members utilizing their mental health benefits for the first time.

07:41 EST DocGo receives ISO 27001 certification for application infrastructure - DocGo announced it has received ISO 27001 certification for its application infrastructure, which includes Ambulnz, a mobile medical services and transportation provider, and HealthPoint, DocGo's patient EMR. The leading international standard for information security, ISO 27001 is published by the International Organization for Standardization in partnership with the International Electrotechnical Commission . To receive this prestigious certification, DocGo underwent a formal, third-party audit to verify that DocGo's existing controls, processes and procedures met the required security standards. The certification is evidence that DocGo complies with the highest international standard, underscoring the company's ongoing commitment to safety and security. "From inception, DocGo's software has been built on a foundation of security and HIPAA-compliance, above all else," said Anthony Capone, President of DocGo. "Receiving the ISO 27001 certification is a testament to our commitment to secure technology. As we grow as an organization and expand our capabilities, we will always continue to prioritize information and data security." DocGo is redefining on-demand access to healthcare, leveraging its AI-powered proprietary technology and expert healthcare professionals. The company delivers Mobile Health services at scale for hospital networks, governmental entities, and enterprise customers to provide high-quality, highly affordable care to patients when and where they need it most. DocGo's mobility solutions, enabled through highly coordinated logistics and focus on exceptional patient care, gives patients much-needed access to medical attention outside of the traditional four walls of the medical establishment.

07:40 EST Boxed to acquire MaxDelivery, terms not disclosed - Boxed announced the signing of a definitive agreement to acquire MaxDelivery, one of New York's first on-demand grocery delivery services. The transaction is expected to close in December 2021, subject to certain undisclosed financial terms and customary closing conditions. The company said, "MaxDelivery provides New Yorkers with a fast, easy, and convenient way to have a broad assortment of groceries delivered directly to their door on-demand, through its one-hour delivery service in Manhattan. Since its inception in 2004, MaxDelivery has consistently delivered premium quality service to its customers, processing approximately 2 million orders to date. MaxDelivery differentiates itself from other ultrafast delivery businesses due to its high average order values of approximately $100, helping yield a history of strong unit economics. Further, all of its employees are full time W-2s, as opposed to 1099 contractors, which allows MaxDelivery to offer consistent quality service, driving customer loyalty with approximately 98% of orders coming from repeat customers each year. Through the acquisition, Boxed will broaden its capabilities in micro dark-store fulfillment and rapid on-demand grocery delivery. Boxed customers in select markets will also enjoy a significantly expanded fresh assortment offering. MaxDelivery will also become a client of Boxed's Software & Services, adopting its proprietary commerce technology to help enable scalability of its operations, and expansion into additional markets over time." On June 13, 2021, Boxed and Seven Oaks Acquisition, a publicly-traded special purpose acquisition company, entered into a definitive agreement relating to the business combination that would result in Boxed becoming a public company upon the closing of the transaction.

07:32 EST Aptose Biosciences to hold corporate update on December 13 - Aptose Biosciences announced that the company management team will provide a corporate update on Monday, December 13, 2021 at 5:30 PM ET, in conjunction with participation at the 2021 ASH Annual Meeting. The event will include a review of HM43239 data highlighted in an oral presentation at ASH, as well as the up-to-date clinical status of luxeptinib. HM43239 is an oral, myeloid kinome inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia. Luxeptinib is an oral, dual lymphoid and myeloid kinome inhibitor in a Phase 1 a/b trial in patients with relapsed or refractory B cell malignancies who have failed or are intolerant to standard therapies, and in a separate Phase 1 a/b trial in patients with relapsed or refractory AML or high risk myelodysplastic syndrome.

07:31 EST Verrica Pharmaceuticals announces resubmission of NDA for VP-102 - Verrica Pharmaceuticals announced that it has resubmitted the New Drug Application for VP-102 for the treatment of molluscum contagiosum to the U.S. Food and Drug Administration. The resubmission is limited to those sections and elements of the NDA that were identified as deficiencies in the Complete Response Letter issued by the FDA in September 2021. The resubmission addresses the successful resolution of inspection deficiencies identified at a contract manufacturing organization in the CRL, as well as the recommendations included in the General Advice Letter received from the FDA that relate to VP-102's user interface.

07:28 EST Battalion Oil announces strategic refinancing - Battalion Oil Corporation announced it has closed an agreement with a group of lenders for a new first lien delayed draw term loan facility for up to $235 million bearing interest of LIBOR plus 7.00% on drawn amounts. Initial borrowings of $200 million will allow Battalion to repay all outstanding loans and obligations under the Company's previous senior revolving credit facility and add significant cash to the balance sheet after fees and expenses. The Company will have approximately $35 million of additional capacity under the Term Loan which will be available for future development of the Company's Monument Draw asset.

07:26 EST Soluna launches curtailment assessment service for clean power producers - Soluna Holdings announced that it is now offering a custom estimating service for clean energy power plant owners and developers looking to reduce costly curtailment problems. The custom Curtailment Assessment is an NDA-protected review of proprietary, project-level data to estimate both lost and recoverable revenue with the addition of flexible offtake of curtailed power by Soluna's modular data centers.

07:25 EST Atai Life Sciences increases ownership position in Compass Pathways - atai Life Sciences (ATAI) announced that it has increased its ownership interest in COMPASS Pathways (CMPS), from 19.4% to 20.8%. This equity stake increase is a demonstration of atai's confidence in COMPASS Pathways and in the potential of COMP360 in mental health care, following the recent COMP360 data in treatment-resistant depression. This solidifies atai's position as COMPASS' largest shareholder. Over 300 million people worldwide live with depression and, of these, a third struggle with TRD that cannot be managed by currently available options.1,2 COMPASS's Phase 2b trial of COMP360 psilocybin in TRD is the largest and most robust trial ever to be conducted with psilocybin. Participants in this COMPASS trial had previously failed on two to four antidepressants. The 233-patient, 22-site, randomized, controlled, double-blind dose-controlled trial with COMP360 reported rapid and durable results in reducing depression, when combined with psychological support, and was generally well tolerated. A single 25mg dose achieved a 6.6 point reduction, from baseline to week three, on the Montgomery-Asberg Depression Rating Scale, successfully meeting the primary endpoint. Most standard selective serotonin reuptake inhibitor antidepressants were approved on just a 2-3 MADRS point reduction in a general major depressive disorder patient population, and several weeks are typically required to show a significant benefit. Another comparable, intranasal esketamine has demonstrated only a 4 MADRS point reduction at 28 days vs. placebo in TRD, thus highlighting the potential of COMP360 in this challenging patient population. Despite the mounting problem of mental health in recent years, further compounded by the pandemic, innovation has been sorely lacking; only seven new treatments have been approved by the FDA for psychiatric disorders since 2015.. In 2018, COMP360 received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for TRD.8 COMPASS has recently expanded the indications of interest to post-traumatic stress disorder and initiated an additional Phase 2 study. COMPASS also reported positive signals from an open-label investigator-initiated study in the U.S. of COMP360 for depression in cancer.9,10 COMPASS' Phase 3 study of psilocybin in TRD is anticipated to launch in 2022. Furthermore, COMPASS is exploring the potential of COMP360 towards several further potential indications including type 2 bipolar disorder depression, anorexia nervosa, body dysmorphia, suicidal ideation and autism. The company said, "As we ultimately believe there is no one-size-fits-all solution in the treatment of mental health conditions, atai is progressing a pharmacologically-diverse array of programs, spanning psychedelics, non-psychedelics, and is developing innovative digital therapeutics to address the areas of highest unmet need in mental health. By developing COMP360 and other novel 5-HT2a agonists, COMPASS is highly complementary to our diversified platform and fully aligns with our vision to heal mental health disorders, so that everyone, everywhere can live a more fulfilled life."

07:21 EST Capstone Green Energy, PowerTap sign licensing, manufacturing agreement - PowerTap Hydrogen Capital is pleased to announce that it has signed a strategic manufacturing and licensing agreement with California-based Capstone Green Energy for the prototype manufacturing of PowerTap's proprietary 3rd generation hydrogen production and dispensing station. Each PowerTap Unit is modular in design and utilizes PowerTap's proprietary technology to produce and dispense blue hydrogen onsite. PowerTap is focused on meeting the large deficiency in hydrogen infrastructure via its unique PowerTap 3 on-site hydrogen production and fueling system. PowerTap's patented solution includes a compact SMR technology to create on-site hydrogen production versus traditional offsite production methods. As a result of the new strategic agreement, Capstone Green Energy will manufacture the small footprint product for PowerTap for use in fueling stations and as part of Capstone's distributed energy low emission microgrid solutions. The PowerTap 3rd generation turns natural gas, including renewable natural gas, into onsite hydrogen and intends to leverage an innovative carbon capture system.

07:19 EST Gritstone says Omnicron variant has minimal impact on TCEs in COVID-19 vaccines - Gritstone bio announced that the SARS-CoV-2 T cell epitopes administered within its self-amplifying mRNA COVID-19 vaccines are minimally impacted by mutations found within the Omicron variant, reinforcing the platform's potential to address emerging variants of concern. The recently described Omicron variant, first identified in South Africa on November 9, 2021, was designated a Variant of Concern by the World Health Organization on November 26, 2021. Early evidence suggests that Omicron carries an increased risk of re-infection, and sequence analysis has revealed many mutations in Spike, including both the N terminal domain and receptor binding domain, which may reduce clinical effectiveness of existing vaccines and/or therapeutic antibodies. Gritstone's CORAL program is a second-generation SARS-CoV-2 vaccine platform delivering a stabilized Spike protein and highly conserved TCEs derived from other SARS-CoV-2 viral genes, offering the potential for more durable protection and broader immunity against SARS-CoV-2 variants. Delivery vectors can comprise self-amplifying mRNA, a chimpanzee adenovirus, or both. Sequence analysis suggests that Gritstone's TCEs are minimally impacted by Omicron. Specifically, of the 146 non-Spike TCE delivered within Gritstone's vaccine currently in clinical trials in the UK and US, only 3 are impacted by Omicron. Similar minimal impact of Omicron is observed in two new vaccine TCE constructs expected to enter clinical trials in South Africa before year end.

07:16 EST Krystal Biotech says GEM-3 trial met primary endpoint, secondary endpoint - Krystal Biotech announced topline results from the pivotal GEM-3 trial of investigational beremagene geperpavec, now known as VYJUVEK, for the treatment of dystrophic Epidermolysis Bullosa. The primary endpoint of the trial evaluated complete wound healing of topical VYJUVEK compared to placebo at six-month timepoints and met statistical significance. VYJUVEK is the first non-invasive, topical and redosable gene therapy in development, and the only genetically corrective approach to treat dystrophic EB that has successfully completed a double blinded Phase 3 trial. Highlights of Topline Results from the GEM-3 Trial: 31 patients were enrolled and evaluable for safety and efficacy per the primary intent-to-treat analysis; 67% of wounds treated with VYJUVEK achieved the primary endpoint of investigator assessed complete wound healing at the six-month timepoints as compared to 22% of wounds treated with placebo. 71% of wounds treated with VYJUVEK achieved the secondary endpoint of investigator assessed complete wound healing at the three-month timepoints as compared to 20% of wounds treated with placebo: 51.0%. In an ad-hoc analysis, the trial also demonstrated a statistical difference between the active and placebo groups for wounds that demonstrated complete wound healing at both the three- and six-month timepoints VYJUVEK was well tolerated. No drug-related serious adverse events or discontinuations due to treatment were reported. One mild drug-related adverse event was reported during the trial. The immunogenicity profile of VYJUVEK was consistent with the prior GEM-1/2 study where we observed no meaningful change in anti-HSV-1 or anti-COL7 antibodies. Based on these results, Krystal intends to file a Biologics License Application with the U.S. Food and Drug Administration in the first half of 2022 as the first step in executing its global regulatory and commercialization strategy to bring this investigational therapy to patients in need. The Company expects to submit a Marketing Authorization Application in Europe shortly after the BLA. Exploration of the potential regulatory path forward in other geographies, including Japan, is underway. Krystal will continue to manufacture VYJUVEK using the commercial scale process at its in-house cGMP manufacturing facility, ANCORIS, which was designed to support potential launch. The Company is currently constructing its second, larger, facility ASTRA, which is expected to come on-line in 2022 to help support a potential global launch and the pipeline.

07:13 EST EHang appoints PwC as new auditor - EHang Holdings announced the appointment of PricewaterhouseCoopers Zhong Tian as its independent registered public accounting firm, effective November 29, 2021, in connection with the audit of the Company's consolidated financial statements for the fiscal year ended December 31, 2021. PwC succeeds Ernst & Young Hua Ming LLP, which previously was the independent registered accounting firm providing audit services to the Company. The change of the Company's independent registered public accounting firm was made after a careful and thorough evaluation process and has been approved by EHang's Audit Committee and the Board of Directors. EY's audit reports on the Company's consolidated financial statements as of and for the years ended December 31, 2019 and 2020 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles. During the years ended December 31, 2019 and 2020 and the subsequent interim period preceding November 29, 2021, there has been no disagreements between the Company and EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which, if not resolved to the satisfaction of EY, would have caused it to make reference to the disagreements in its audit reports

07:12 EST Altus Power, Shell announce collaboration on sustainability solutions - Altus Power and Shell New Energies US (RDS.A;RDS.B) announced they will collaborate to bring integrated renewable energy and storage solutions to customers to help them reduce their carbon emissions and lower their energy costs. The collaboration will leverage each firm's respective strengths. Altus Power will bring its experience in creating clean electrification ecosystems, which includes solar generation, storage and community solar, while Shell will bring its capabilities in electric mobility, stationary battery storage, load management and renewable power supply. Together both companies will explore opportunities to develop fully integrated renewable energy supply and onsite energy services for customers as well as for property portfolios managed by CBRE Group (CBRE). CBRE has a strategic partnership with Altus Power, and CBRE Acquisition Holdings (CBAH), a special-purpose acquisition company sponsored by a subsidiary of CBRE, is in the process of completing a business combination with Altus Power that will result in Altus Power being a publicly traded company.

07:08 EST SSR Mining announces Copper Hill exploration results, increases ownership to 70% - SSR Mining announces "positive" results from an additional 27 diamond drill holes at Copper Hill for the period from June to September 2021. Copper Hill is located in the Black Sea region of northeast Turkey, and these results follow the initial 8 drill holes reported from the prospect in 2020. Recent intercepts1 of note from Copper Hill included: EKD-09: 2.02% Cu over 30.5 meters from 44.7 meters, EKD-10: 3.03% Cu over 31.5 meters from 107.5 meters, EKD-12: 2.37% Cu over 13.0 meters from 213.6 meters, EKD-14: 1.60% Cu over 30.1 meters from 65.7 meters, EKD-16: 3.29% Cu over 37.4 meters from 92.0 meters, EKD-26: 1.02% Cu over 80.5 meters from 123.5 meters, EKD-30: 1.39% Cu over 36.0 meters from 122.0 meters, and EKD-32: 1.25% Cu over 33.4 meters from surface. SSR Mining also announces that it has reached an agreement to acquire an additional 20% ownership in Copper Hill from joint venture partner Lidya Mining. Upon completion of the Transaction, SSR Mining will own 70% of the asset and serve as operator. As consideration for the increased ownership in Copper Hill, SSR Mining will transfer 20% of its ownership stake in the Tuncpnar prospect in east-central Turkey to Lidya Mining, reducing SSR Mining's ownership to 30% while retaining a new 0.5% net smelter return royalty on the property. Lidya Mining will serve as operator at Tuncpnar. There are no royalties existing on Copper Hill. The Transaction will be completed in early 2022. Rod Antal, President and CEO said, "Copper Hill is beginning to show real potential as a new development project, particularly given the near-surface and high-grade mineralization. While still early stage, there is good potential to expand the footprint at Copper Hill as we step out exploration drilling. Our exploration and development teams will accelerate the work on Copper Hill, commencing with metallurgical test work and an expanded drilling program."

07:07 EST Flora Growth signs licensing agreement with Tonino Lamborghini - Flora Growth announced that the company has signed a licensing agreement with Tonino Lamborghini to produce and distribute Tonino Lamborghini branded cannabis beverages across North America and Colombia under their renowned luxury lifestyle brand. The Tonino Lamborghini product line will be produced through Flora's division and contain CBD and other premium cannabinoids such as cannabigerol. Under the licensing deal, Flora will retain the right of first refusal to produce and distribute any CBD or CBG products globally under the Tonino Lamborghini brand. The products will be produced in Florida initially for sale in U.S. states where CBD ingestible are legal. Flora will be responsible for production and distribution and will target both ecommerce and brick-and-mortar channels.

07:06 EST G1 Therapeutics initiates Phase 2 trial of trilaciclib with Trodelvy - G1 Therapeutics announced that the Company has initiated a Phase 2, single arm, open-label study of trilaciclib administered prior to the antibody-drug conjugate, Trodelvy in patients with unresectable locally advanced or metastatic triple-negative breast cancer. Antitumor efficacy and myeloprotective endpoints are being assessed in this trial. Initial results of this study are expected in the second half of 2022. Patient recruitment in this trial is now underway. Approximately 40 patients will be enrolled in this exploratory Phase 2, multicenter, open-label, single arm study evaluating the safety and efficacy of trilaciclib administered prior to sacituzumab govitecan-hziy in patients with unresectable, locally advanced or metastatic TNBC who received at least 2 prior treatments, at least 1 in the metastatic setting. Trilaciclib will be administered as a 30-minute IV infusion completed within 4 hours prior to the start of sacituzumab govitecan-hziy treatment on day 1 and day 8 of each 21-day cycle. Study drug administration will continue until progressive disease per Response Evaluation Criteria in Solid Tumors v1.1 or clinical progression as determined by the Investigator, unacceptable toxicity, withdrawal of consent, Investigator decision, or the end of the study, whichever occurs first. The primary objective is to evaluate the anti-tumor efficacy of trilaciclib when administered prior to sacituzumab govitecan-hziy as measured by progression-free survival. Key secondary endpoints include evaluation of the anti-tumor efficacy as measured by the objective response rate, duration of objective response, clinical benefit rate, and overall survival; and evaluation of the myeloprotective effects of trilaciclib.

07:05 EST Lee Enterprises comments on purported director nominations from Alden - Lee Enterprises commented on the purported notice submitted by Alden seeking to nominate three candidates to stand for election to Lee's board of directors at the company's 2022 annual meeting. Lee issued the following statement in response: "Early last week, Lee promptly and properly denied a request from Alden seeking certain nomination materials because Alden failed to comply with the clear and substantive requirements of Lee's bylaws. Alden did not subsequently submit a revised request. Instead, late in the afternoon of the Company's Friday, November 26 nomination deadline, Alden submitted a purported notice of nominations. Consistent with its fiduciary duties and in consultation with its advisors, Lee's Board of Directors will carefully review Alden's purported notice for compliance with the nomination procedures and the information, documentation and other requirements that have been set forth in Lee's publicly available bylaws for over two years. After completion of its review of Alden's purported notice, Lee will provide further information to shareholders."

07:04 EST Olaplex Holdings, Ulta Beauty announces expansion of distribution partnership - Olaplex Holdings announced the expansion of its distribution with Ulta Beauty. Building on OLAPLEX's success with its recent launch of professional hair products in Ulta Beauty salons, the Company's retail products will be available at each of the leading beauty retailers' more than 1,250 stores and on ulta.com beginning January 2022. The Company noted that the expansion of its retail products into Ulta Beauty was already reflected in the previously disclosed fiscal 2021 guidance provided on November 10, 2021.

07:02 EST Shawcor receives LOI from third party to purchase Rexdale property - Shawcor announced its plan to expand and modernize its manufacturing capabilities in the Greater Toronto Area. Shawcor has received a Letter of Intent from a third party to purchase its Rexdale property in Toronto, ON and is in the process of negotiating a definitive purchase and leaseback agreement that is expected to generate net proceeds in excess of C$45 million. Pursuant to the LOI, the Company would be required to enter into a three-year leaseback arrangement for the Rexdale property to facilitate operational continuity while ultimately moving to a modernized location. Proceeds from the property sale will be used to reduce existing indebtedness. The sale and leaseback of the Rexdale facility remains subject to normal conditions for a transaction of this type and is expected to close during the first half of 2022. The Company also announced the sale of its Guardian Mexico entity and the closure of its CSI Services entity in Western Canada, which in combination accounted for roughly C$8.6 million of revenue and C$0.4 million of EBITDA in the last twelve months, as at September 30, 2021. These actions serve to narrow Shawcor's focus to those businesses that are best positioned to benefit from favourable long-term macro trends.

07:00 EST NRx Pharmaceuticals completes analysis of ZYESAMI treatment in COVID-19 - NRx Pharmaceuticals announced that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI in patients with Critical COVID-19 and Respiratory Failure over existing therapies such as remdesivir. NRx asked Prof. David Schoenfeld, one of the world's most widely published statisticians with unique expertise in life-threatening diseases of the lung to conduct the analysis. Dr. Schoenfeld analyzed the subgroup of patients in the COVID-AIV trial that remained in respiratory failure despite treatment with remdesivir. The analysis identified a statistically-significant 2.5 fold increased odds of being alive and free of respiratory failure at 60 days and a statistically significant four-fold higher odds of being alive at day 60 among patients treated with aviptadil compared to those treated with placebo. Baseline treatment with remdesivir was prespecified as a covariate in the protocol agreed to with the US Food and Drug Administration prior to initiation of the trial and remdesivir did not show any independent survival or recovery advantage in the subgroup. Analysis of the remdesivir-treated subgroup was a post-hoc analysis performed in response to the FDA's request for additional clinical evidence that aviptadil may demonstrate a substantial improvement over existing therapies. The reanalysis of the clinical trial data additionally confirmed a statistically-significant two-fold survival advantage seen across all patients treated with aviptadil compared to those treated with placebo and demonstrated an increased odds of reaching the primary endpoint in the study, being both alive and free of respiratory failure at 60 days that approached statistical significance. The FDA recently declined Emergency Use Authorization and Breakthrough Therapy Designation for ZYESAMI and invited a new request based on new clinical evidence that aviptadil may demonstrate a significant improvement in treatment over existing therapies. Based on FDA's input, NRx has narrowed its requested BTD indication to "Treatment of COVID-19 Respiratory Failure in patients who progress despite treatment with remdesivir and other approved therapies."

06:57 EST SpringsWorks Therapeutics announces full enrollment of Phase 2b ReNeu trial - SpringWorks Therapeutics announced that it has achieved full enrollment in its Phase 2b ReNeu trial evaluating mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with NF1-associated plexiform neurofibromas. The study enrolled over 50 adults and over 50 pediatric patients with NF1-PN. SpringWorks expects to provide an update on anticipated ReNeu trial timelines and milestones at an upcoming company-sponsored R&D Day. The ReNeu trial is a multi-center, open-label Phase 2b trial evaluating the efficacy, safety, and tolerability of mirdametinib in patients two years of age and older with an inoperable NF1-associated PN causing significant morbidity. Patients receive mirdametinib at a dose of 2 mg/m2 twice daily without regard to food. Mirdametinib is administered in a 3-week on, 1-week off dosing schedule. The primary endpoint of the ReNeu trial is objective response rate defined as greater than or equal to 20% reduction in target tumor volume as measured by MRI and assessed by blinded independent central review. Secondary endpoints include safety and tolerability measures, duration of response, and changes from baseline in patient reported outcomes.As previously disclosed, interim data from the first 20 adult patients enrolled in the ReNeu trial were presented at the 2021 Children's Tumor Foundation NF Conference and showed encouraging efficacy and tolerability. As of the March 23, 2021 data cutoff date, 50% of patients had achieved an objective response as assessed by blinded independent central review, 80% remained on study, and median time on treatment was 13 cycles. Among these patients, mirdametinib was generally well tolerated, with the majority of treatment-related adverse events being Grade 1 or 2; only one Grade 3 TRAE and no Grade 4 or 5 adverse events were reported in these 20 patients.

06:55 EST Drive Shack to bring Puttery to Philadelphia's Fishtown neighborhood - Drive Shack announced it will bring Puttery, its newest competitive socializing and entertainment golf experience, to the bustling area between Old Kensington and Fishtown in Philadelphia. Located just a short El ride from Center City, Puttery Philadelphia will be part of a mixed-use retail redevelopment project in Fishtown, one of the area's most historic neighborhoods. The 20,000-square-foot venue will feature three uniquely themed, nine-hole putting courses, multiple bars, and a chef-driven menu and incredible cocktail program, adding to Fishtown's already booming nightlife and culinary scenes.

06:54 EST Karuna Therapeutics appoints Charmaine Lykins as CCO - Karuna Therapeutics announced the appointment of Charmaine Lykins as chief commercial officer, effective November 29, 2021. Ms. Lykins most recently served as the Senior Vice President, Global Product Planning and Chief Marketing Officer for ACADIA, where she oversaw their healthcare professional and consumer marketing, marketing operations and new product planning functions.

06:51 EST European Commission approves KEYTRUDA plus LENVIMA for advanced RCC - Merck and Eisai announced that the European Commission has approved the combination of KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for the first-line treatment of adult patients with advanced RCC. The approval for advanced RCC is based on results from the pivotal Phase 3 CLEAR /KEYNOTE-581 trial, in which KEYTRUDA plus LENVIMA demonstrated statistically significant improvements versus sunitinib in the efficacy outcome measures of progression-free survival, reducing the risk of disease progression or death by 61% with a median PFS of 23.9 months versus 9.2 months for sunitinib, and overall survival, reducing the risk of death by 34% versus sunitinib. Median OS was not reached at the time of analysis in either study arm. The objective response rate was 71% for patients treated with KEYTRUDA plus LENVIMA versus 36% for patients treated with sunitinib. Patients treated with KEYTRUDA plus LENVIMA achieved a complete response rate of 16% and partial response rate of 55% versus a CR rate of 4% and a PR rate of 32% for patients treated with sunitinib. The safety of KEYTRUDA in combination LENVIMA was evaluated in 497 patients with advanced RCC. The most frequently reported adverse reactions were diarrhea, hypertension, fatigue, hypothyroidism, decreased appetite, nausea, stomatitis, proteinuria, dysphonia and arthralgia. This approval allows marketing of KEYTRUDA plus LENVIMA in all 27 EU member states plus Iceland, Liechtenstein, Norway and Northern Ireland. KEYTRUDA plus LENVIMA is now approved by the European Commission for two different types of cancer: for the first-line treatment of adult patients with advanced renal cell carcinoma and for advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation.

06:47 EST Ancora urges Berry Global to commit to review of strategic alternatives - Ancora Holdings Group announced that it has sent a letter to Berry Global Group, Inc.'s Board of Directors. The company said, "Ancora Holdings Group is a shareholder of Berry Global Group, with ownership of approximately one percent of the Company's outstanding shares. We believe Berry has a high-quality portfolio of packaging products and a unique value proposition to offer the global manufacturing sector. We also believe Berry has a capable management team that deserves credit for driving meaningful sales growth and earnings improvements in recent years. However, despite these tailwinds, Berry has been a chronic underperformer that perpetually trades at a significant discount to the broader market, relevant indices and packaging peers. In our view, it is time for the Board of Directors to take real action to address the impediments to value creation that have compounded at Berry. We deem Wednesday afternoon's announcement of $50 million in planned share repurchases to be an insult to investors. Not only is the size of the accelerated share repurchase transaction wholly insufficient, but the Board did not even increase its existing authorization. As total shareholder returns have lagged in recent years, the Board has repeatedly failed to establish an accretive capital allocation policy and seize opportunities to monetize non-core real estate assets. It is now necessary to initiate a comprehensive review of strategic alternatives, including a full sale or go-private transaction. We have spent significant energy and time analyzing Berry's operational and financial performance since Tom Salmon became Chief Executive Officer in February 2017. Mr. Salmon has presided over a 113.4% increase in annual revenues, an 83.8% increase in annual EBITDA and, most importantly, a 134.3% increase in diluted earnings per share. Regrettably, these results have been accompanied by a paltry 29.7% share price uptick during his nearly five-year tenure.1 Additionally, we remain concerned by Berry's acquisition track record and leverage philosophy. Shareholders have historically suffered as the Company, which was previously saddled with immense debt, pursued deals with excessively high leverage ratios, causing its shares to trade at an acute discount. But even now that the Company's leverage ratio is within its target range, its shares still continue to underperform the market. This suggests to us that Berry's persistent valuation discount is linked to the risk of the Board continuing to allocate capital to acquisitions, rather than simply being the result of the Company's leverage ratio. A credible capital allocation policy that prioritizes returning cash to shareholders could be one remedy for Berry's punishing valuation gap.We believe Ancora is not the only shareholder that feels the Board should commit to reviewing its existing strategy relative to alternatives. In recent months, we have had conversations with a number of fellow shareholders who expressed their own concerns about Berry's share price stagnation and valuation discount. Certain shareholders, including us, now believe they may be best served by seeing the Company sold to one of the many well-capitalized financial sponsors and strategic buyers in the marketplace. A review of relevant and comparable acquisitions indicates shareholders could receive $100 per share or more in value via a sale. It is unclear whether the current Board has a viable plan for unlocking that type of value on a standalone basis any time soon..As noted, we believe the Board needs to promptly commence a review of strategic alternatives. The review should be communicated publicly so that shareholders can see that the Board is taking its fiduciary duties seriously. We believe that a strong Board that is in tune with its shareholders would actively address the concerns of engaged shareholders. Playing hide-the-ball with information on the direction of the Company after a prolonged period of stagnation runs counter to what we believe are sound governance practices maintained by a well-functioning Board. First and foremost, we believe the Board should consider repurchasing additional shares with Berry's ample free cash flow and capital on hand. In light of the Company's strong profitability, it is particularly well-positioned to buy back stock at current levels. Not only would a large and ongoing repurchase program be accretive for Berry, but it would also send a strong message to investors that leadership has confidence in the business going forward. We suggest that the Board immediately announces an expansion of its repurchase authorization to $1 billion. Another logical step is a sale-leaseback transaction. If Berry is concerned about balance sheet flexibility and having sufficient cash to fund strategic growth, then it should consider funding share repurchases through a sale-leaseback transaction that will generate significant cash. We estimate Berry has up to $2 billion in real estate value currently tied up on its balance sheet, and that a transaction with the right buyer could provide the Company with nearly 20% of its market capitalization in cash. Seizing this opportunity would allow the Board to quickly upsize its $400 million "opportunistic" repurchase authorization to $1 billion or more in size, while still retaining capital for prudent investments. Lastly, we believe the Board owes it to long-suffering shareholders to evaluate a sale of the Company or a go-private transaction. Ancora, in particular, views this step as an absolute necessity given the public market's unwillingness to properly value Berry. Rather than taking action to aggressively combat the low valuation multiple, the Board has spent years allowing management to run the Company like a private business with an ultra-long-term investment horizon, translating to a lack of return of capital to shareholders. In light of the aforementioned factors, the Board should hire a qualified investment bank to run a market test. Our own analysis of comparable transactions indicates Berry could fetch a valuation of $100 per share or more via a sale."

06:43 EST Sage Therapeutics to host Sage FutureCast webcast - Sage Therapeutics announced that it will host Sage FutureCast: An R&D and Portfolio Review on Tuesday, December 14 from 8:00 a.m. to 10:00 a.m. ET. Sage FutureCast will discuss the Company's research and development strategy, and clinical progress in programs throughout the depression, neurology, and neuropsychiatry franchises including zuranolone, SAGE-324 and SAGE-718, respectively.

06:40 EST Cathie Wood's ARK Investment bought 317.3K shares of Exact Sciences on Friday

06:38 EST Manchester United appoints Ralf Rangnick as interim manager - Manchester United is delighted to announce the appointment of Ralf Rangnick as Interim Manager until the end of the season, subject to work visa requirements. Following this period, Ralf and the club have agreed that he will continue in a consultancy role for a further two years. Michael Carrick will remain in charge of the First Team until Ralf's work visa is finalised.

06:35 EST EnPro appoints Eric Vaillancourt as president, CEO - EnPro Industries announced that its Board of Directors has appointed Eric Vaillancourt as President and CEO and as a member of the Company's Board effective immediately. Mr. Vaillancourt has served as Interim President and CEO since August 2021 and previously served as President of Enpro's Sealing Technologies segment. Mr. Vaillancourt joined Enpro in 2009 as Vice President, Sales & Marketing at Garlock, where he served until 2012, when he was elevated to President, Garlock.

06:21 EST Land 'N' Sea reports sales at annual trade shows - In 2020, Land 'N' Sea introduced its "Buy with Confidence" virtual program during the height of the COVID-19 pandemic, hosting its shows including the annual Kellogg/Land 'N' Sea show virtually and reporting a 40 percent increase in sales compared with their in-person shows in 2019. This year, Land 'N' Sea returned to an in-person event at the Mohegan Sun Expo Center in Connecticut while retaining a digital experience for their other shows, and just reported an additional 30% increase in sales over last year's record show season. Additionally, in-person attendance increased almost 20% compared with the last physical show in Connecticut in '19. LNS also hosted two additional shows virtually this year, both with extremely successful sales. The company said, "The success of both the 2020 and 2021 events indicates excitement and a strong appreciation among attendees for hybrid show formats as a potential long-term solution for the Land 'N' Sea distribution shows."

06:18 EST Origin Sports Network expands distribution partners - Origin Sports Network has expanded its lineup of distribution partners to include The Roku Channel and Samsung TV Plus, more than quadrupling its addressable audience size. A 24/7 linear streaming network, Origin Sports brings viewers unique content featuring Hall of Famers, All-Americans, All-Stars, No. 1 picks and National Champions before they became household names. Leveraging Raycom's more than four decades of award-winning production expertise, Origin Sports launched in July with distribution on The Roku Channel in Canada and on XUMO in the United States, along with YouTube, Facebook, Twitter and Instagram. Pairing nostalgic throwback content with original programming, Origin Sports is the destination for instant-classic comebacks, unforgettable performances, compelling stories and epic endings. Featuring legendary athletes like Michael Jordan, Bo Jackson, Shaquille O'Neal and Joe Montana - to current superstars like Patrick Mahomes, Josh Allen, Devin Booker and Zion Williamson - there's something for sports fans of all ages and eras! Leveraging both the Raycom Sports and Gray TV archives, Origin Sports delivers seldom seen footage to today's fans on their favorite platforms.

06:12 EST Newegg announces opening of limited trading window for restricted shares - Currently, approximately 365 million of the Company's outstanding common shares remain subject to various transfer restrictions contained in Newegg's Amended and Restated Shareholders Agreement dated October 23, 2020 or its 2005 Incentive Award Plan. In addition, all of the shares issuable under the 2005 Incentive Award Plan and the 2021 Equity Incentive Plan are also subject to various transfer restrictions set forth in those plans. Over the next three weeks, beginning Tuesday, November 30, 2021 and ending Friday, December 17, 2021, inclusive of those dates, the Company will allow a strictly controlled, temporary waiver of these transfer restrictions to enable limited trading of common shares by its employees, former employees, officers, directors, and stockholders who received restricted common shares of the Company as part of the merger between Newegg Inc. and Lianluo Smart Limited. Each such employee, former employee, officer, director, or stockholder, together with their respective affiliates, is referred to below as a "Restricted Holders." As of November 26, 2021, there were approximately 96 Restricted Holders, who will be limited to selling an aggregate of 1,575,463 shares during the Trading Window. The two largest Restricted Holders, Hangzhou Liaison Interactive Information Technology Co., Ltd., and Mr. Fred Faching Chang, will be limited to selling 408,750 and 245,250 shares, respectively, with daily sales limits of not more than the lesser of 5% of daily volume or 27,250 for Hangzhou Liaison Interactive Information Technology Co., Ltd., and the lesser of 3% of daily volume or 16,350 for Mr. Fred Faching Chang during the Trading Window. All other Restricted Holders will be limited to selling 921,463 shares in total, with daily sales limits from zero to 5,500 common shares per Restricted Holder per trading day, during the Trading Window. Newegg may decide to further limit, but not expand, the volume limitations imposed on such Restricted Holders in its sole discretion during the Trading Window based on prevailing market conditions and other factors. No sales would be allowed by the Restricted Holders when the NASDAQ stock market is closed. Based on recent historical trading volumes, the Company expects that aggregate sales by the Restricted Holders could comprise a material portion of the trading volume during the Trading Window; however, the actual number of common shares offered for sale by Restricted Holders is subject to their own discretion, within the limits described above, and could vary from the Company's expectations. The Trading Window provides Restricted Holders with the opportunity to obtain some liquidity for their common shares and vested stock options, while also gradually increasing the size of the public float for Newegg common shares. After the Trading Window closes on December 17, all trading restrictions contained in the 2005 Incentive Award Plan, 2021 Equity Incentive Plan, and the Shareholders Agreement will be in full effect in accordance with their original terms and restrictions. However, the Company intends to allow Restricted Holders to adopt customary trading plans under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, subject to similar volume limitations described above. These plans will likely result in continued sales of the Company's common shares into the public market after December 17, 2021.

06:10 EST Newegg Commerce announces grant of restricted stock units - Newegg approved the grant of 7.4 million restricted stock unit awards to its executive officers and key employees. These grants vest over four years, with 25% vesting on the one-year anniversary of grant, and the remainder vesting monthly over the following three years, such that they will be fully vested after four years. The grants total approximately 2% of the current outstanding share count for Newegg. One half of the grants, or 3,687,450 RSUs, were granted to the company's Chief Executive Officer, Anthony Chow. The remaining executives received grants as follows: 280,000 RSUs awarded to Newegg's Chief Operating Officer, Jamie Spannos, 150,000 RSUs to Chief Financial Officer, Robert Chang, 150,000 RSUs to Chief Technology Officer, Montaque Hou, and 100,000 RSUs to Chief Legal Officer, Brian Waters. The remaining 3,007,450 RSUs were granted or reserved for 252 other key employees or expected new hires. All grants were made pursuant to a newly adopted 2021 Equity Incentive Plan, which has authorized shares under the plan of 7.4 million shares. After the RSU grant, there are no further shares available under the 2021 Equity Incentive Plan.

06:06 EST DaVita study indicates effectiveness of COVID-19 vaccines in dialysis patients - Dialysis patients who received mRNA COVID-19 vaccines had a lower risk of COVID-19 diagnosis post-vaccination and were less likely to be hospitalized or die following breakthrough infection than unvaccinated patients, according to a DaVita Clinical Research study published online ahead of print by the Journal of the American Society of Nephrology. To assess COVID-19 vaccine effectiveness in this patient population, researchers evaluated electronic health records of 35,206 DaVita dialysis patients vaccinated with Pfizer/BioNTech or Moderna vaccines between January 1 and February 25. These patients were matched to unvaccinated controlled groups and followed over time to observe future COVID-19 infections and related clinical outcomes. Researchers observed that the Pfizer/BioNTech and Moderna vaccines were 78% and 73% effective in preventing COVID-19 infections, respectively. The study indicated that vaccinated dialysis patients who experienced a breakthrough COVID-19 infection were also less likely to be hospitalized or die from COVID-19 as compared to unvaccinated patients diagnosed with COVID-19. In addition, among vaccinated dialysis patients, SARS-CoV-2 antibodies were detected in rates similar to those seen in the broader Phase III clinical trials.

06:04 EST Applied DNA Sciences announces Linea 2.0 COVID-19 Assay kit - Applied DNA Sciences announced its COVID-19 diagnostic strategy in response to the emergence of Omicron, a newly identified SARS-CoV-2 variant of concern. The Company plans to introduce its Linea 2.0 COVID-19 Assay, a new RT-PCR assay for the SARS-CoV-2 E and N genes that builds on the Company's established COVID-19 line of diagnostics, after submission of its validation data to the New York State Department of Health in the next few days. The Company also announced that its EUA-authorized Linea COVID-19 Assay Kit likely exhibits a unique double S-gene target failure specific to the Omicron variant. While other assays have been shown to have SGTF based on the presence of the undefined69-70 mutation contained in Omicron, this specific mutation is shared across several SARS-CoV-2 lineages and is not specific to the new variant. Based on the Company's initial analysis, the Company believes that the combination of mutations that cause the unique double SGTF in the Linea 1.0 Assay is unique to Omicron. This unique double SGTF may result in false negative results in patients infected with the Omicron variant when tested with the Linea 1.0 Assay as a primary diagnostic. This unique pattern may, however, allow the Linea 1.0 Assay to provide a high-specificity reflex test for the Omicron variant. More specifically, the Linea 1.0 Assay may be potentially used as a reflex test to indicate the presence of Omicron in samples that have tested positive for COVID-19 via third-party assays that cannot discriminate for the new variant because these same samples will test negative on the Linea 1.0 Assay due to the unique double SGTF. Analysis in silico of the mutations represented in the Omicron variant's genome sequences publicly available in GISAID shows that neither of the Linea 2.0 Assay targets are affected by the variant's mutations. Validation testing for the Linea 2.0 Assay for both single sample and pooled testing is already complete. The Company intends to submit its validation data as a Laboratory Developed Test to the NYSDOH in the next few days. The validation data for the Linea 2.0 Assay show the performance of the new assay meets or exceeds the performance of the Linea 1.0 Assay.

05:43 EST Newegg Commerce expands into two new distribution centers in Atlanta, Ontario - Newegg Commerce announced its expansion into two new distribution centers located in Atlanta, Georgia and Ontario, California. At more than 200,000 and 240,000 square feet respectively, the facilities are distribution points to help Newegg better serve its customers throughout the country. With a total of eight distribution facilities located throughout the United States, Newegg now has more than 2.1M square feet of warehouse and distribution space in domestic hubs, including Los Angeles, Indianapolis, the New York metropolitan area and now Atlanta.

05:38 EST Thermo Fisher says TaqPath COVID-19 PCR test not impacted by Omicron variant - Thermo Fisher confirmed that its polymerase chain reaction, or PCR, TaqPath COVID-19 Combo Kit, and TaqPath COVID-19 CE-IVD RT-PCR Kit, which test for the presence of SARS-CoV-2, are not impacted by the emerging B.1.1.529, or Omicron variant, enabling accurate test results. The Omicron variant, which was designated a "variant of concern" by the World Health Organization, has more than 30 mutations in the spike protein alone.

05:32 EST Nokia selected by Ooredoo for five-year 5G agreement - Nokia announced that it has been selected by Ooredoo Group to bring multiple technologies and services, including 5G, to customers in Middle East, North Africa and South-east Asia as part of a multi-country, five-year deal. The deal, which builds on Nokia's global partnership with Ooredoo, will see Nokia expand Ooredoo's existing network, as well as introduce new 5G services. The deployment is already underway and is expected to be completed by 2026 in all these countries. Under the deal, Nokia will deploy equipment from its latest AirScale RAN portfolio on sites across North Africa and Southeast Asia. Nokia's AirScale radio platform features the flexibility and capability required for delivering 5G services to consumers and enterprises across different spectrum bands. The deal also includes digital deployment services supporting a faster time to market as well as technical support services.

05:21 EST Skechers, Marcolin renew licensing agreement for Skechers eyeware - Marcolin and Skechers USA announced the renewal of their licensing agreement for the design, production and worldwide distribution of Skechers sunglasses, eyeglasses and kids' eyewear. The partnership has been extended until December 31, 2024. The collection features a range of eye sizes for children and adults. Skechers Eyewear is available at authorized e-commerce retailers as well as select opticians. The sunglasses are sold at independent retailers and department stores as well as in select Skechers retail stores throughout the U.S. and around the world.

05:09 EST ViacomCBS, NENT group partner to launch Pluto TV in the Nordics - ViacomCBS Networks International, or VCNI, a division of ViacomCBS (VIACA), and Nordic Entertainment Group (NENTF), or NENT Group, announced a partnership for a new Pluto TV service across Sweden, Denmark and Norway in 2022. The service combines ViacomCBS' free ad-supported streaming TV, or FAST, service with the biggest pan-Nordic AVOD platform Viafree. NENT Group will serve as the platform's advertising sales partner. Pluto TV will introduce the new FAST/AVOD platform with curated channels and on-demand programming featuring international and local content. Following the launch of Pluto TV, Viafree will be phased out as a stand-alone platform. Pluto TV is available in 26 markets globally, including the U.S., Latin America and Europe.